var title_f15_12_15552="Substernal goiter scan II";
var content_f15_12_15552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Radioiodine scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-Iodine scan showing a cervical and large hyperfunctioning substernal goiter. The enlarged cervical thyroid is indicated by the circle; SSN indicates the suprasternal notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15552=[""].join("\n");
var outline_f15_12_15552=null;
var title_f15_12_15553="NSCLC malig pl eff";
var content_f15_12_15553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large pleural effusion in a 60-year-old man cytologically positive for adenocarcinoma consistent with lung primary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15553=[""].join("\n");
var outline_f15_12_15553=null;
var title_f15_12_15554="Atherosclerotic plaque visualized by 3D TEE";
var content_f15_12_15554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atherosclerotic plaque visualized by 3D TEE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Protruding plaque in the aortic arch.",
"    <br>",
"     (B) Ulcerated plaque in the descending thoracica aorta.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Dr. Muhamed Saric.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15554=[""].join("\n");
var outline_f15_12_15554=null;
var title_f15_12_15555="Smooth nasal foreign bodies avoid forceps";
var content_f15_12_15555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Smooth nasal foreign bodies: avoid forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Attempts at removing a smooth intranasal foreign body with forceps will often push these objects deeper into the nasal cavity. A right angle hook should be used instead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15555=[""].join("\n");
var outline_f15_12_15555=null;
var title_f15_12_15556="Metyrapone: Drug information";
var content_f15_12_15556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metyrapone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43219?source=see_link\">",
"    see \"Metyrapone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12806507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metopirone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diagnostic test:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single-dose/overnight test: 30 mg/kg (maximum: 3 g) at midnight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple-dose test: 750 mg every 4 hours for 6 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cushing&rsquo;s syndrome treatment (unlabeled use):",
"     </b>",
"     Oral: 250 mg 4 times a day (maximum daily dose: 6000 mg) (Biller 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F196007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43219?source=see_link\">",
"      see \"Metyrapone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic test:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Single-dose/overnight test:",
"     </i>",
"     30 mg/kg (maximum: 3 g) at midnight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Multiple-dose test:",
"     </i>",
"     15 mg/kg (minimum: 250 mg; maximum: 750 mg) every 4 hours for 6 doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metopirone&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11345045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metopirone&reg; is available from Novartis Pharmaceuticals via special allocation only. Contact the manufacturer for additional information at 888-669-6682.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11345073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Single-dose test: Administer to patients with adequate waking cortisol concentrations (&gt;200 nmol/L) (Wallace 2009). Administer dose at midnight with yogurt or milk. Blood samples are taken the following morning (7:30-8:00 am). Administer prophylactic dose of cortisone acetate 50 mg after samples are obtained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multiple-dose test: Administer with milk or snack 2 days following ACTH test. Urine is collected for 24 hours following the last day of administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic test for hypothalamic-pituitary ACTH function",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11345046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Cushing&rsquo;s syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Metyrapone may be confused with metyrosine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort or pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow suppression (rare), white blood cell count decreased (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metyrapone or any component of the formulation; patient with adrenal cortical insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reduced adrenal secretory capacity: Acute adrenal insufficiency may be induced in patients with reduced adrenal secretory capacity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Response to test may be subnormal in patients with hypo- or hyperthyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Metyrapone may increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Subnormal response may occur in pregnant women and the fetal pituitary may be affected.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11345047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The excretion of metyrapone and its active metabolite into breast milk are described in a case report. The mother had been taking metyrapone 250 mg 4 times/day for 9 weeks and was 1 week postpartum when milk samples were obtained. Multiple milk samples taken 1-5 hours after the dose contained average concentrations of metyrapone 11.2 mcg/L and metyrapol 48.5 mcg/L over the dosing interval. The relative infant dose (metyrapone and metyrapol) was calculated to be 0.1% of the weight adjusted maternal dose.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11345070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with milk or snack.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Metopirone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (18): $216.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11345076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Single-dose test: 11-deoxycortisol concentrations &lt;200 nmol/L are diagnostic for adrenal insufficiency (Wallace 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multiple dose test: Normal response following the test is a two- to fourfold urinary increase in 17-OHCS excretion or doubling of 17-KGS excretion.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11345075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal 24-hour urinary excretion of 17-OHCS: 3-12 mg (increases following ACTH infusion)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Metopiron (CH, GB, IE, NL, NO, SE);",
"     </li>",
"     <li>",
"      Metopirone (AU, CZ, FR, GR, HK, IL, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11345064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metyrapone inhibits the production of cortisol; blockade can be measured by the urinary increase of the metabolites of cortisol precursors in the urine (17-hyroxycorticosteroids [17-OHCS] and 17-ketogenic steroids [17-KGS]).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11345066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Peak steroid excretion: Within 24 hours of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Reduced to metyrapol (active metabolite); parent drug and metabolite also undergo glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Half-life elimination: Metyrapone: ~1.9 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Time to peak: 1 hour",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Excretion: Urine; ~5% as metyrapone (primarily as glucuronide conjugate) and ~38% as metyrapol (primarily as glucuronide conjugate)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Biller BM, Grossman AB, Stewart PM, et al, \"Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(7):2454-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/12/15556/abstract-text/184134274/pubmed\" id=\"184134274\" target=\"_blank\">",
"        184134274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hotham NJ, Ilett KF, Hackett LP, et al, \"Transfer of Metyrapone and its Metabolite, Rac-Metyrapol, Into Breast Milk,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2009, 25(4):451-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/12/15556/abstract-text/19759353/pubmed\" id=\"19759353\" target=\"_blank\">",
"        19759353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace I, Cunningham S, and Lindsay J. \"The Diagnosis and Investigation of Adrenal Insufficiency in Adults,\"",
"      <i>",
"       Ann Clin Biochem",
"      </i>",
"      ,2009, 46(Pt 5):351-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/12/15556/abstract-text/19675057/pubmed\" id=\"19675057\" target=\"_blank\">",
"        19675057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10156 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15556=[""].join("\n");
var outline_f15_12_15556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806507\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196015\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195998\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196007\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195999\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195988\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195977\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345045\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345073\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195989\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345046\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196020\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196013\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195991\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195980\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196012\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195983\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195985\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195992\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196000\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345047\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345070\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323397\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345076\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345075\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038679\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345064\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11345066\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43219?source=related_link\">",
"      Metyrapone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15557="Thymic carcinoid high power";
var content_f15_12_15557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well-differentiated thymic carcinoid: histologic appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Organoid nests composed of uniform polygonal cells with centrally located nuclei and finely granular nuclear chromatin, forming rosettes, are characteristic features of carcinoid tumors. Necrosis is frequently seen in thymic carcinoid. (Hematoxylin and eosin, magnification 100x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15557=[""].join("\n");
var outline_f15_12_15557=null;
var title_f15_12_15558="Overview of the management of advanced melanoma";
var content_f15_12_15558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of advanced melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15558/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/12/15558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H863138373\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of malignant melanoma are diagnosed at an early stage, when surgical excision can be curative. However, a few patients have metastatic disease at presentation, while some develop metastases after their initial definitive surgery.",
"   </p>",
"   <p>",
"    High-dose interleukin-2 (IL-2) was the first treatment to influence the natural history of patients with metastatic melanoma and may result in cure in a small fraction of patients. However, its severe toxicity limits its application to carefully selected patients treated at centers with experience in managing the side effects of treatment. More recent research has led to the development of immunotherapy using an anti-CTLA4 monoclonal antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ) and to targeted therapy (BRAF inhibition), both of which prolong overall survival compared with chemotherapy.",
"   </p>",
"   <p>",
"    This topic provides an overview of treatment options for patients with metastatic melanoma, along with their application in different clinical settings. More detailed discussions of the specific treatment options are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"       \"Surgical management of metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"       \"Molecularly targeted therapy for metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"       \"Cytotoxic chemotherapy for metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link\">",
"       \"Management of brain metastases in melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863137073\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches that can provide clinically important benefit for appropriately chosen subsets of patients with metastatic melanoma include surgical metastasectomy, immunotherapy, targeted inhibition of the MAP kinase pathway, and radiation therapy to symptomatic sites of metastases. Although cytotoxic chemotherapy was widely used prior to the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and targeted therapies, it does not have an established role for patients with metastatic melanoma.",
"   </p>",
"   <p>",
"    Additional novel approaches are under active development. Patients should be encouraged to enroll in clinical trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311232\">",
"    <span class=\"h2\">",
"     Surgical metastasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with one or a very limited number of metastases, initial surgical excision of all metastatic disease can delay the need for systemic treatment and occasionally produces durable benefit. Metastasectomy may also have an important role in eradicating residual disease for patients who have had a good response to immunotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"     \"Surgical management of metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311240\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy has an established role in the treatment of metastatic melanoma; established immunotherapy approaches include high-dose interleukin-2 (IL-2) and the anti-CTLA4 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    . Patients who have an ongoing response to immunotherapy should be reassessed for possible metastasectomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High dose IL-2 &ndash; Immunotherapy with high-dose interleukin-2 (IL-2) is associated with long-term disease-free survival in a small minority of treated patients and may result in cure. Treatment with high-dose IL-2 is limited by its severe toxicities (cardiovascular, respiratory, infectious) to patients with excellent organ function who are treated by experienced clinicians in specialized programs capable of providing the necessary intensive care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       Ipilimumab",
"      </a>",
"      &ndash; Ipilimumab is a monoclonal antibody that targets CTLA-4, thus unleashing an immune reaction against the tumor. Treatment with ipilimumab significantly increases median overall survival in both previously untreated and previously treated patients with metastatic or unresectable melanoma. Prolonged responses have been observed after ipilimumab therapy, which apparently are similar to those observed with high dose IL-2. Responses to immunotherapy may develop slowly and patients may have a transient worsening of disease before disease stabilizes or tumor regresses. Prior treatment with high dose IL-2 does not preclude a benefit from subsequent treatment with ipilimumab. Ipilimumab is associated with a variety of clinically significant autoimmune side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For good performance status patients who have access to appropriate specialized programs, we prefer high-dose IL-2 as the initial immune based therapy option.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is an alternative when IL-2 is not available or appropriate; it can also be used sequentially after IL-2 in some cases. The administration of high dose IL-2 after ipilimumab may incur additional toxicities and little information is available on its efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311247\">",
"    <span class=\"h2\">",
"     MAPK pathway inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of melanomas have a V600 BRAF mutation that activates the MAPK pathway. BRAF inhibition produces rapid tumor regression in the majority of patients with V600 mutant melanoma, including those with an extensive tumor burden and disease-related symptoms. Inhibition of BRAF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    or dabrafenib significantly increases overall survival in patients with metastatic melanoma and these mutations. Treatment is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Continued treatment is necessary to maintain a response, and the majority of patients develop progressive disease within 6 to 12 months. In cases where there are isolated sites of progression, a combination of local therapy and continued administration of BRAF inhibitor may be the best approach [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15558/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with disseminated progression this approach has not been pursued. However, there are data that patients may respond to vemurafenib after progression when rechallenged at a later time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311262\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy may have a palliative role for symptomatic localized areas of disease. Radiation therapy, particularly with stereotactic radiosurgery, may be particularly important for patients with brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link\">",
"     \"Management of brain metastases in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311269\">",
"    <span class=\"h2\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy (single agent or combination) has not been shown to improve overall survival in patients with advanced melanoma. Response rates are typically less than 20 percent and median response durations are four to six months. Consequently the role of chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    , fotemustine) is limited to patients who are not candidates for treatment with high-dose IL-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    and those who have progressed after optimal treatment with other options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179147766\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metastatic melanoma should undergo a detailed evaluation prior to treatment to assess the extent of disease because the likelihood of detecting additional, unsuspected lesions is high. This includes pathologic confirmation of metastatic disease, molecular characterization of the tumor, whole body imaging (CT of the chest, abdomen, and pelvis and MRI of the brain), and serum LDH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H6#H6\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Stage IV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link\">",
"     \"Imaging studies in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863137387\">",
"    <span class=\"h1\">",
"     CHOICE AND SEQUENCE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy (high-dose IL-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ) and targeted therapy (inhibiting the MAPK pathway) have established clinical roles based upon significant rates of durable remission (high-dose IL-2, ipilimumab) or prolongation of overall survival (ipilimumab, BRAF inhibitors). In contrast, cytotoxic chemotherapy has not been shown to increase survival or to induce durable remission; chemotherapy thus is generally limited to patients who are not candidates for further treatment with either immunotherapy or targeted therapy, and for whom there is no appropriate clinical trial.",
"   </p>",
"   <p>",
"    There are no randomized trials that compare high-dose IL-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , and BRAF inhibitors with each other. Multiple factors should be considered in choosing treatment for an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311294\">",
"    <span class=\"h2\">",
"     Mutation status of tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have their tumors assayed for the presence or absence of a driver mutation at the V600 site in BRAF. The presence of such a mutation determines whether a patient is likely to respond to a BRAF inhibitor. BRAF inhibitors do not have a role in the treatment of patients without a V600 BRAF mutation. When available, genotyping for other driver mutations (eg, KIT, NRAS) should also be considered, since that information may determine eligibility for alternative research protocols and may provide useful prognostic information.",
"   </p>",
"   <p>",
"    Patients with other mutations in the MAPK pathway (NRAS) also appear to be more likely to respond to high-dose IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15558/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186311305\">",
"    <span class=\"h2\">",
"     Extent of disease and sequence of therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with disease limited to one or a very limited number of sites, evaluation by a surgical oncologist is indicated to determine whether complete resection of all metastatic disease is feasible as the initial treatment. Although widespread metastatic disease develops in most cases, complete resection of metastatic disease is associated with prolonged survival in some cases. In addition, patients who initially are not candidates for metastasectomy and who have a good response to immunotherapy (high dose IL-2,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      ) should be reevaluated after completion of their immunotherapy to determine whether they are candidates for metastasectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"       \"Surgical management of metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When metastasectomy is not an option, asymptomatic or minimally symptomatic patients with a normal serum LDH and metastatic disease limited to skin, subcutaneous tissues, distant lymph nodes, or lung (M1a or M1b) tend to have a better prognosis and relatively slowly progressive disease (",
"      <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"       table 1A-B",
"      </a>",
"      ). In this setting, immunotherapy is generally preferred regardless of the BRAF mutation status of the tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link&amp;anchor=H552584207#H552584207\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\", section on 'High-dose IL-2'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H19256013#H19256013\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Long-term duration of response'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have access to appropriate specialized programs and do not have significant comorbidity, we prefer high-dose IL-2 as the initial immune based therapy options. High-dose IL-2 results in prolonged duration of response and may be associated with cure in some cases.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       Ipilimumab",
"      </a>",
"      is an alternative when IL-2 is not available or appropriate; prolonged responses have been observed after ipilimumab therapy, which apparently are similar to those observed with high dose IL-2. Ipilimumab can also be used sequentially after IL-2 in some cases. The administration of high dose IL-2 after ipilimumab may incur additional toxicities and little information is available on its efficacy.",
"     </li>",
"     <li>",
"      When disease can no longer be controlled with immunotherapy, targeted therapy with BRAF inhibition is indicated for those whose tumor contains a V600 BRAF mutation. BRAF inhibition has been associated with prolongation of overall survival. Continued treatment is necessary to maintain a response, and the majority of patients develop progressive disease within 6 to 12 months. For those whose tumor does not contain such a mutation, enrollment in a clinical trial or cytotoxic chemotherapy may be options. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In contrast, those with bulky disease, other visceral metastases, an elevated serum LDH (M1c), or a poor performance status are more likely to have rapidly progressive disease and a shorter overall survival. In this situation, the more rapid response associated with targeted therapy, if indicated based upon molecular testing, may be advantageous as an initial approach. BRAF inhibition can prolong overall survival in this setting, although has not been associated with durable remissions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Those who have bulky or rapidly progressive disease but are negative for a BRAF mutation are generally candidates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      immunotherapy, which can prolong overall survival. Clinical trial participation or chemotherapy may be options when progressive disease develops. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"       \"Cytotoxic chemotherapy for metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863137233\">",
"    <span class=\"h2\">",
"     Metastasis directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected situations, locoregional therapy may play an important role in the management of patients with advanced melanoma. Brain metastases are particularly common in patients with melanoma, and MRI of the brain is indicated at the initial presentation with metastatic disease. The presence of symptomatic central nervous system metastases requires therapeutic intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H13565191#H13565191\">",
"     \"Management of brain metastases in melanoma\", section on 'Immunotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179148215\">",
"    <span class=\"h1\">",
"     FOLLOW-UP DURING AND AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to studies dictated by the presence of new symptoms, careful follow-up is required during and after treatment so that necessary changes in treatment regimens can be made if there is evidence of disease progression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are being managed with immunotherapy and who achieve a complete response or near complete response, our approach is to repeat CTs of the chest, abdomen, and pelvis every three months for the first two years, along with an MRI of the head every six months. Both CT and MRI are repeated every six months during year three, and then annually through year five. After year five, we monitor simply with a chest x-ray.",
"     </li>",
"     <li>",
"      For patients who are being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      , our approach is to repeat scans every three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H863137163\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary systemic therapy options for patients with metastatic melanoma are immunotherapy (high dose IL-2,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      ) and targeted therapy. Targeted therapy has not been compared with immunotherapy in randomized trials. The appropriate choice and sequence of treatments for an individual patient is based upon the extent of disease, molecular characteristics of the tumor (BRAF mutation present or not), and patient performance status and comorbidity. (See",
"      <a class=\"local\" href=\"#H863137073\">",
"       'Treatment options'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H863137387\">",
"       'Choice and sequence of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients whose metastatic disease is limited to one or a very limited number of sites should be evaluated for the possible surgical metastasectomy. Although widespread metastatic disease develops in most cases, complete resection of metastatic disease is associated with prolonged survival in some cases. Systemic therapy is indicated for patients in whom surgical metastasectomy is not appropriate. (See",
"      <a class=\"local\" href=\"#H186311232\">",
"       'Surgical metastasectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"       \"Surgical management of metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without a V600 BRAF mutation, we recommend immunotherapy (high dose IL-2 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      ) rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Targeted therapy is not indicated in patients without a characteristic V600 mutation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For good performance status patients who have access to appropriate specialized programs, we suggest high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. Ipilimumab can be used sequentially after IL-2 in some patients.",
"     </li>",
"     <li>",
"      For patients with a poor performance status or untreated brain metastases who thus are not candidates for high dose IL-2, we recommend immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H327750098#H327750098\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Previously untreated patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients whose disease can no longer be controlled with immunotherapy, options include enrollment in a clinical trial or cytotoxic chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a good performance status, we suggest immunotherapy rather than targeted therapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The preference for immunotherapy is based upon the prolonged disease control achieved with immunotherapy in some patients, whereas those treated with targeted therapy almost always relapse relatively rapidly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have access to appropriate specialized programs, we suggest high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. Ipilimumab can be used sequentially after IL-2 in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a V600 BRAF mutation who were initially treated with immunotherapy and whose disease can no longer be controlled with either high dose IL-2 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      , we recommend targeted therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      ) rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"       \"Molecularly targeted therapy for metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a poor performance status, we suggest targeted therapy rather than immunotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      is an alternative. Immunotherapy may be an option for second line therapy when patients progress after targeted therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"       \"Molecularly targeted therapy for metastatic melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15558/abstract/1\">",
"      Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15558/abstract/2\">",
"      Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012; 35:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85841 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15558=[""].join("\n");
var outline_f15_12_15558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H863137163\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H863138373\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H863137073\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311232\">",
"      Surgical metastasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311240\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311247\">",
"      MAPK pathway inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311262\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311269\">",
"      Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179147766\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H863137387\">",
"      CHOICE AND SEQUENCE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311294\">",
"      Mutation status of tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186311305\">",
"      Extent of disease and sequence of therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H863137233\">",
"      Metastasis directed therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179148215\">",
"      FOLLOW-UP DURING AND AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H863137163\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15559="Sudden cardiac arrest in the absence of apparent structural heart disease";
var content_f15_12_15559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sudden cardiac arrest in the absence of apparent structural heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15559/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/12/15559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained pulseless ventricular tachycardia or ventricular fibrillation. The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCA and SCD occur most commonly in patients with structural heart disease (including previously undiagnosed heart disease), particularly coronary heart disease. SCD in the apparently normal heart (at autopsy) is an uncommon occurrence that is responsible for only 10 to 15 percent of cases of SCD. The majority of SCD patients without apparent structural heart disease likely do not actually have \"normal\" hearts, but our diagnostic tools limit identification of structural or functional derangement. In the past, the etiology of many of these deaths was unknown and deemed \"idiopathic.\" However, more complete evaluation has identified the cause of death as a primary electrical disorder (ie, Long QT or Brugada Syndrome) in many of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCD in the apparently normal heart will be reviewed here. SCD in patients with heart disease, and the evaluation and options for the management of survivors of SCD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\", section on 'Etiology of SCD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, sudden death may occur from noncardiac causes (eg, trauma, pulmonary embolism seizure), and these topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=see_link\">",
"     \"Sudden unexpected death in epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon a review of death certificates in the United States during 1998 and 1999, sudden cardiac death (SCD) accounted for over 450,000 deaths, which represented 63 percent of cardiac deaths among adults &ge;35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of SCD is increased six- to tenfold in the presence of clinically recognized heart disease (",
"    <a class=\"graphic graphic_figure graphicRef52309 \" href=\"UTD.htm?24/42/25261\">",
"     figure 1",
"    </a>",
"    ); it also increases with age and is two to three times more common in men than women (",
"    <a class=\"graphic graphic_figure graphicRef59028 \" href=\"UTD.htm?18/4/18509\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the risk of SCD is higher in patients with structural heart disease, SCD events occur in individuals with apparently normal hearts. In a series of 121 SCD cases where data on left ventricular function was available, 48 percent had normal left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/6\">",
"     6",
"    </a>",
"    ]. Among these patients, one-half had no history of established coronary heart disease.",
"   </p>",
"   <p>",
"    Autopsy studies of subjects with a presumed diagnosis of SCD have shown that up to approximately 20 percent do not have a demonstrable cardiac abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ]. A lower value of about 5 percent has been described in autopsy studies and among survivors of SCD when older patients are included, a population in which coronary heart disease (CHD) is more prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In the largest reported autopsy series of 902 cases of SCD (mean age 38 years), 187 (21 percent) had no evidence of cardiac pathology that could cause SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/9\">",
"     9",
"    </a>",
"    ]. Atherosclerotic CHD appears markedly more common as the cause of SCD in victims who are 35 years of age or older (incidence 13.7 per 100,000 person-years versus 0.7 per 100,000 person years without CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of cardiac causes of SCD varies with age, the population studied, and geography. While coronary heart disease (CHD) is listed as the underlying cause of SCD on the majority of death certificates among the general population in the United States, younger patients, athletes, and those without known prior disease often have a different distribution of causes. The etiology of SCD is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several major diseases must be considered as possible causes of sudden cardiac death (SCD) in patients without evidence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/3\">",
"     3",
"    </a>",
"    ]. Many of these disorders are familial and therefore are associated with an increased risk of SCD in first-degree relatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     WPW and other forms of SVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both Wolff-Parkinson-White (WPW) syndrome and, very rarely, other forms of supraventricular tachycardia (SVT) can cause sudden cardiac death (SCD). The frequency with which this occurs was assessed in a report of 290 patients with aborted SCD. The mechanism was an arrhythmia associated with the WPW syndrome in 2.1 percent; atrial fibrillation (AF) with a rapid ventricular response was the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/10\">",
"     10",
"    </a>",
"    ]. A similar incidence of preexcitation (3.6 percent) was noted in a report of 273 children and young adults with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/11\">",
"     11",
"    </a>",
"    ]. The epidemiology and clinical manifestations of the WPW syndrome are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who have been resuscitated from ventricular fibrillation (VF) secondary to preexcitation have a previous history of atrioventricular reciprocating tachycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/12\">",
"     12",
"    </a>",
"    ]. However, preexcitation and arrhythmias have been previously undiagnosed in up to 25 percent of such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Among patients with WPW syndrome who survive an episode of SCD, ablation of the accessory pathway is the treatment of choice. All treatment options for persons with the WPW syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long QT can be inherited (the Long QT Syndrome [LQTS]) or acquired (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78934 \" href=\"UTD.htm?8/61/9179\">",
"     table 2",
"    </a>",
"    ) and may be associated with a specific form of polymorphic ventricular tachycardia (VT) called torsades de pointes (",
"    <a class=\"graphic graphic_waveform graphicRef53891 \" href=\"UTD.htm?42/23/43380\">",
"     waveform 1",
"    </a>",
"    ). Among patients with inherited LQTS, the precipitating factors and prognosis vary with the genetic abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between sudden cardiac death (SCD) and therapeutic levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/15\">",
"     15",
"    </a>",
"    ]. The mechanism for this association may be QT prolongation and drug-induced torsades de pointes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Catecholaminergic polymorphic VT with normal QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who develop polymorphic ventricular tachycardia (VT) have a normal QT interval, in contrast to those with long QT. Affected patients typically present with life-threatening VT or ventricular fibrillation occurring during emotional or physical stress, with syncope often being the first manifestation of the disease. Although sporadic cases occur, this is a largely familial disease that is also called catecholaminergic polymorphic VT. The majority of known cases are due to mutations in the cardiac ryanodine receptor, which is the cardiac sarcoplasmic calcium release channel. One report suggested that this disorder may account for at least one in seven cases of sudden unexplained death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/16\">",
"     16",
"    </a>",
"    ]. Other causes of polymorphic VT in the setting of a normal QT interval include cardiac ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Brugada syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada syndrome is characterized by the electrocardiographic findings of right bundle branch block and ST-segment elevation in leads V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"     waveform 2",
"    </a>",
"    ), and an increased risk of sudden cardiac death. Brugada syndrome is due to a functional abnormality in the electrical activity of the heart (primary electrical disease), although there are some data that some individuals may have an early subclinical manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC). The syndrome occurs in families, with genetic transmission consistent with autosomal dominant inheritance with variable penetrance. Mutations in the cardiac sodium channel gene, SCN5A, have been found in several families. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sudden unexpected nocturnal death syndrome (SUNDS) has also been described in young, apparently healthy males from Southeast Asia. This disorder is closely related to Brugada syndrome, since a majority of affected patients have the ECG manifestations of the Brugada syndrome and the same mutations in the sodium channel gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different mutations of the same SCN5A gene have been found in a number of cardiac disorders, including the long QT syndrome, and a unique allele found in African Americans, Y1102. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 3'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Short QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short QT Syndrome (SQTS) is an extremely rare inherited channelopathy (disorder which affects the movement of ions through channels with the cell membrane) associated with marked shortened QT intervals and SCD in individuals with a structurally normal heart. In contrast to long QT syndrome, another channelopathy, ion channel defects associated with SQTS lead to abnormal abbreviation of repolarization, predisposing affected individuals to a risk of atrial and ventricular arrhythmias. SQTS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=see_link\">",
"     \"Short QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Commotio cordis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commotio cordis is defined as sudden cardiac death secondary to relatively innocent chest wall impact, usually due to ventricular fibrillation. Affected patients have no underlying heart disease and there is no structural damage to the chest wall, thoracic cavity, or the heart. Early defibrillation of commotio victims is lifesaving, despite historical evidence that resuscitation may be more difficult in commotio cordis than in other forms of SCD. Commotio cordis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"     \"Commotio cordis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Idiopathic VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the above disorders are excluded and the heart is structurally normal, the diagnosis of primary electrical disease is made [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/3,17,18\">",
"     3,17,18",
"    </a>",
"    ]. More commonly referred to as idiopathic ventricular fibrillation (VF), this entity is estimated to account for 5 percent of cases of sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/17\">",
"     17",
"    </a>",
"    ]. In a review of 54 published cases with presumed idiopathic VF, the mean age was 36 years with a male-to-female ratio of 2.5-to-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/18\">",
"     18",
"    </a>",
"    ]. A history of syncope preceded the episode of VF in 25 percent.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of idiopathic VF, particularly its inclusion as part of the early repolarization syndrome, is presented in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=see_link\">",
"     \"Early repolarization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599199\">",
"    <span class=\"h2\">",
"     Familial SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of sudden cardiac death (SCD) in the absence of apparent structural heart disease is associated with an increased risk for primary SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. It has been estimated that the adjusted relative risk for SCD, compared with controls, is 1.6 to 1.8 in individuals without apparent structural heart disease in whom a first-degree relative had SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, the absolute increase in risk is quite small since primary SCD is rare in the general population.",
"   </p>",
"   <p>",
"    Some of these families have an inherited cardiac disease, as illustrated in a report in which 147 first-degree relatives of 32 patients with SCD underwent detailed cardiological assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/21\">",
"     21",
"    </a>",
"    ]. Seven (22 percent) of the 32 families had an inherited cardiac disease, including four with long QT syndrome, one with myotonic dystrophy, and one with hypertrophic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOPSY AND MOLECULAR GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience sudden cardiac death (SCD), particularly young patients, should undergo an autopsy with extensive cardiac evaluation to evaluate for the presence of structural heart disease. Many of the cardiac diseases, such as Wolff-Parkinson-White syndrome (WPW) and arrhythmogenic right ventricular cardiomyopathy (ARVC), may be missed on standard autopsies. As noted, inherited arrhythmia syndromes are common in individuals who experience SCD but whose autopsy reveals no evidence of structural heart disease. Diagnosing such a syndrome would have significant implications for surviving family members, particularly if a specific genetic defect could be identified. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Evaluation of family members'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, genetic testing of the victim of SCD with a structurally normal heart should occur. Although interpretation may be limited by the large number of candidate genes, the number of known mutations in each of these genes and variable gene expression and penetrance, continued development and knowledge of the gene pool database will be important for the management of the surviving relatives.",
"   </p>",
"   <p>",
"    As both genetic testing techniques and our understanding of these heritable disorders improve, genetic screening at specialized centers has yielded diagnoses in up to one-third of young SCD victims without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest reported series of 173 cases of sudden death (mean age 18 years, 61 percent male, 89 percent white) with traditional autopsy negative for cause of death, molecular autopsy was performed with genetic testing to assess for mutations in five long QT syndrome genes as well as the RYR2 gene for catecholaminergic polymorphic ventricular tachycardia (CVPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/23\">",
"     23",
"    </a>",
"    ]. Forty-five pathogenic mutations (26 percent) were identified, including 25 (14.4 percent) in long QT genes and 20 (11.6 percent) in RYR2 gene for CPVT, with a significantly higher prevalence of genetic mutations identified in females (39 percent versus 18 percent in males). Patients with genetic abnormalities and sudden death during exercise were more likely to have a mutation in the RYR2 gene for CPVT, while those with abnormalities and sudden death at rest were more likely to have a mutation in a long QT gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION OF SURVIVORS OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of survivors of sudden cardiac arrest (SCA) in patients with apparently normal hearts involves a variety of tests, including genetic analysis. These tests are performed in an effort to exclude drug or toxin exposure or underlying structural heart disease which may have contributed to SCA. In addition, a rigorous search for the known causes of SCA should be performed in the apparently healthy person prior to making the diagnosis of idiopathic VF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15559/abstract/3\">",
"     3",
"    </a>",
"    ]. An extensive discussion of the evaluation of SCA survivors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EVALUATION OF FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, many causes of sudden cardiac death (SCD) in patients with structurally normal hearts are familial, and therefore are associated with an increased risk of SCD in first-degree relatives. In families of victims of unexplained SCD, a general cardiology evaluation of first- and second-degree relatives can yield diagnosis of a heritable disease in up to 40 percent of families. A discussion of the evaluation of family members of victims of unexplained SCD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link&amp;anchor=H23#H23\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Evaluation of family members'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166108\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden cardiac death (SCD) refers to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF). SCD is the most common cause of cardiovascular death in the developed world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the risk of SCD is higher in patients with structural heart disease, as many as 10 to 15 percent of SCDs occur in individuals with apparently normal hearts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of SCD with a normal heart are (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Potential causes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wolff-Parkinson-White syndrome",
"     </li>",
"     <li>",
"      Long QT syndrome",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic VT with normal QT interval",
"     </li>",
"     <li>",
"      Brugada syndrome",
"     </li>",
"     <li>",
"      Short QT syndrome",
"     </li>",
"     <li>",
"      Commotio cordis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Commotio cordis is defined as sudden cardiac death secondary to relatively innocent chest wall impact, usually due to ventricular fibrillation. Affected patients typically have no underlying heart disease and there is usually no structural damage to the chest wall, thoracic cavity, or the heart. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"       \"Commotio cordis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A family history of SCD (in first-degree relatives) in the absence of apparent structural heart disease is associated with an increased risk for primary SCD. (See",
"      <a class=\"local\" href=\"#H599199\">",
"       'Familial SCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who experience SCD, particularly young patients, should undergo a standard autopsy to evaluate the presence of structural heart disease. In young patients, if there is no clear diagnosis after autopsy, genetic testing now can yield a diagnosis in up to one third of young SCD victims and should generally be performed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Autopsy and molecular genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of sudden cardiac arrest (SCA) should undergo extensive testing to exclude drug or toxin exposure or underlying structural heart disease that may have contributed to SCA. Therapy with an implantable cardioverter-defibrillator should generally be recommended in survivors of SCA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"       \"Evaluation of the survivor of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In families of victims of unexplained SCD, a general cardiology evaluation of first- and second-degree relatives can yield diagnosis of a heritable disease in up to 40 percent of families. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link&amp;anchor=H23#H23\">",
"       \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Evaluation of family members'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/1\">",
"      Myerburg RJ. Sudden cardiac death in persons with normal (or near normal) hearts. Am J Cardiol 1997; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/2\">",
"      Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/3\">",
"      Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004; 43:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/4\">",
"      Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/5\">",
"      Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/6\">",
"      Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/7\">",
"      Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/8\">",
"      Bowker TJ, Wood DA, Davies MJ, et al. Sudden, unexpected cardiac or unexplained death in England: a national survey. QJM 2003; 96:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/9\">",
"      Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/10\">",
"      Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991; 18:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/11\">",
"      Basso C, Corrado D, Rossi L, Thiene G. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation 2001; 103:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/12\">",
"      Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol 2003; 41:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/13\">",
"      Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/14\">",
"      Montoya PT, Brugada P, Smeets J, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991; 12:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/15\">",
"      Chugh SS, Socoteanu C, Reinier K, et al. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008; 121:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/16\">",
"      Tester DJ, Spoon DB, Valdivia HH, et al. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004; 79:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/17\">",
"      Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/18\">",
"      Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990; 120:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/19\">",
"      Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998; 97:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/20\">",
"      Jouven X, Desnos M, Guerot C, Ducimeti&egrave;re P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/21\">",
"      Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. Lancet 2003; 362:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/22\">",
"      Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007; 49:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15559/abstract/23\">",
"      Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87:524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1019 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15559=[""].join("\n");
var outline_f15_12_15559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H166108\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WPW and other forms of SVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Catecholaminergic polymorphic VT with normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Idiopathic VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599199\">",
"      Familial SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOPSY AND MOLECULAR GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION OF SURVIVORS OF SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EVALUATION OF FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H166108\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1019|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25261\" title=\"figure 1\">",
"      SCD and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/4/18509\" title=\"figure 2\">",
"      Incidence of sudden death in men and women increases with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 1\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/61/9179\" title=\"table 2\">",
"      Ranges for corrected QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1019|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 1\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 2\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=related_link\">",
"      Sudden unexpected death in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15560="Diagnostic and therapeutic abdominal paracentesis";
var content_f15_12_15560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic and therapeutic abdominal paracentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15560/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/12/15560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H337673727\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal paracentesis is a simple bedside procedure in which a needle is inserted into the peritoneal cavity and ascitic fluid is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnostic paracentesis refers to the removal of a small quantity of fluid for testing. Therapeutic paracentesis refers to the removal of 5 liters or more of fluid to reduce intra-abdominal pressure and relieve the associated dyspnea, abdominal pain, and early satiety [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the indications, contraindications, technique, and complications of abdominal paracentesis. Ascitic fluid analysis and the differential diagnosis of ascites are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673734\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several generally accepted indications for abdominal paracentesis (",
"    <a class=\"graphic graphic_table graphicRef65249 \" href=\"UTD.htm?8/54/9067\">",
"     table 1",
"    </a>",
"    ). In addition to helping to clarify the cause of ascites and evaluating for infection, it can identify unexpected diagnoses, such as chylous, hemorrhagic, eosinophilic ascites, and tuberculous peritonitis. In one report, approximately 5 percent of patients with cirrhosis and bacterial infection of their ascitic fluid had a surgically-treatable cause such as a perforated viscus or abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98542912\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF NOT DELAYING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic paracentesis should be performed promptly, especially in patients in whom there is the possibility of spontaneous bacterial peritonitis in whom a delay in initiating therapy can increase mortality. In our experience, delays have often been due to a lack of availability of staff experienced with paracentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    undue concern about its safety. In some settings, the procedure is performed by interventional radiologists, which not only causes a delay but has the potential to lead to miscommunication regarding appropriate testing of samples. It can be helpful to the interventional radiologist for the clinician of record to preprint labels for the desired tests and to send those labels with the patient. This prevents confusion regarding which tests are requested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673748\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of abdominal paracentesis in patients with appropriate indications almost always outweigh the risks. An analysis of the fluid helps determine the cause(s) of the ascites and the likelihood of bacterial infection, and it can identify antibiotic susceptibility of the organism that is cultured.",
"   </p>",
"   <p>",
"    On the other hand, there are certain absolute and relative contraindications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with clinically apparent disseminated intravascular coagulation and oozing from needle sticks probably should not undergo paracentesis. This occurs in",
"      <span class=\"nowrap\">",
"       &lt;1/1000",
"      </span>",
"      patients with ascites in our experience.",
"     </li>",
"     <li>",
"      Primary fibrinolysis (which should be suspected in patients with large, three-dimensional bruises) is probably another contraindication. Paracentesis can be performed once the bleeding risk is reduced with treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paracentesis should not be performed in patients with a massive ileus with bowel distension unless the procedure is image-guided to ensure that the bowel is not entered.",
"     </li>",
"     <li>",
"      The location of the paracentesis should be modified in patients with surgical scars so that the needle is inserted several centimeters away from the scar. Surgical scars are associated with tethering of the bowel to the abdominal wall, increasing the risk of bowel perforation. Bowel perforation by the paracentesis needle occurs in approximately",
"      <span class=\"nowrap\">",
"       6/1000",
"      </span>",
"      taps. Fortunately, it is generally well tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98542919\">",
"    <span class=\"h2\">",
"     Coagulopathy is not an absolute contraindication",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequent concern in performing paracentesis is the almost universal presence of some degree of coagulopathy in patients with decompensated cirrhosis. However, multiple studies have documented the safety of paracentesis in such patients without prophylactic transfusion of blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illustrative, prospective study of 1100 large-volume paracenteses documented no bleeding complications with no pre-procedure and no post-procedure transfusions despite INRs as high as 8.7 and platelet counts as low",
"      <span class=\"nowrap\">",
"       19,000/cu",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report (in which occasional patients received prophylactic plasma, platelets or DDAVP), severe bleeding was observed in only 9 out of 4729 paracenteses (0.19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/9\">",
"       9",
"      </a>",
"      ]. The mortality rate attributable to the procedure was 0.016 percent. Eight of the nine patients who bled had renal failure, suggesting that the qualitative platelet dysfunction associated with renal failure contributed to the bleeding risk. Thus, it may be reasonable to use DDAVP before performing paracentesis in patients with cirrhosis and renal failure, although no studies have formally established a benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"       \"Platelet dysfunction in uremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A somewhat higher complication rate (1.6 percent) was reported in a prospective study of 515 procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/10\">",
"       10",
"      </a>",
"      ]. Five patients bled, three developed infections, and two died. However, one of the complications was related to \"catheter residue broken into abdominal wall,\" which together with the relatively high complication rate raises concerns as to whether there were specific technique-related factors that may have contributed to the adverse outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion of blood product to reverse the coagulopathy before paracentesis is discouraged since it is",
"    <strong>",
"     not",
"    </strong>",
"    supported by the available data, can delay the procedure, exposes the patient to risk of transfusion, and is costly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/6-8,11\">",
"     6-8,11",
"    </a>",
"    ]. Furthermore, standard measures of coagulation status (such as the INR) do not accurately reflect the degree of coagulopathy and risk of bleeding in patients with advanced liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98543447\">",
"    <span class=\"h1\">",
"     WHO SHOULD PERFORM PARACENTESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracentesis can be performed safely by any clinician who has received proper training. The American Board of Internal Medicine used to require three successful supervised paracenteses as a minimum standard of competency; this requirement has been waived [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/12\">",
"     12",
"    </a>",
"    ]. Some hospitals have a dedicated procedure team that performs simple procedures such as paracentesis and central line insertion. Such teams typically include a qualified, experienced clinician or mid-level provider, an assistant, and an ultrasound machine to guide the procedure. As noted above, the availability of adequately trained staff is imperative to prevent delays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673755\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients do not need to be fasting before the procedure. We have performed thousands of paracenteses and have never held food or fluids by mouth in advance of the procedure.",
"   </p>",
"   <p>",
"    Informed consent should be obtained (",
"    <a class=\"graphic graphic_table graphicRef73987 \" href=\"UTD.htm?33/45/34523\">",
"     table 2",
"    </a>",
"    ). An ultrasound machine should be made available as needed, depending on the comfort level and experience of the operator. Sometimes this requires scheduling and coordinating with the ultrasonography department.",
"   </p>",
"   <p>",
"    We try to make the procedure as efficient as possible by",
"    <span class=\"nowrap\">",
"     writing/entering",
"    </span>",
"    orders for the ascitic fluid tests that we are planning to obtain. We prefer to have specimen labels and order forms available before beginning the procedure.",
"   </p>",
"   <p>",
"    In addition, we assemble all supplies that could be needed before beginning (",
"    <a class=\"graphic graphic_table graphicRef73987 \" href=\"UTD.htm?33/45/34523\">",
"     table 2",
"    </a>",
"    ). Even if a simple therapeutic paracentesis is anticipated (in which we typically obtain only a cell count and differential), the appearance of the fluid or the patient's clinical features may prompt additional testing. As an example, bacterial cultures should be obtained in patients with clinical features suggestive of infection.",
"   </p>",
"   <p>",
"    Some clinicians use gowns, caps, and sterile (surgical) drapes for paracentesis. We have used a non-sterile (isolation) gown, no cap, and no sterile drape for decades and have had essentially no contaminated culture bottles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to have a sharp receptacle box on the floor near the procedure area so that needles can be discarded immediately without having to walk across the room to a wall-mounted sharp disposal container. This minimizes the chance of a needle stick. A wastebasket is also a useful item to have readily available to discard other items to minimize clutter on the bedside tray, which can also help minimize the chance of a needle stick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673762\">",
"    <span class=\"h1\">",
"     PATIENT POSITION AND NEEDLE ENTRY SITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracentesis is usually performed with the patient supine. The bed or gurney is either flat, or the head is slightly elevated. Rarely the patient can be positioned prone on \"all fours\" or spanning two gurneys. This position is used only when there is a small amount of fluid and the suspected diagnosis is crucial to the patient's outcome (eg, tuberculous peritonitis). The face-down position with the fluid pooled in the dependent abdomen permits drainage of the last few mL of fluid.",
"   </p>",
"   <p>",
"    In the past, the midline, cephalad from the umbilicus, was frequently used as the site of needle entry because of its relative avascularity. However, the recanalized umbilical vein may be present caudad to the umbilicus in the midline, an area that should be avoided.",
"   </p>",
"   <p>",
"    However, the midline approach is now seldom used since most paracenteses (about 90 percent) are therapeutic and many patients are obese [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/2,10,14\">",
"     2,10,14",
"    </a>",
"    ]. Furthermore, a prospective study showed that the abdominal wall was thinner in the left lower quadrant than in the midline and that the pool of fluid was deeper in the left lower quadrant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/15\">",
"     15",
"    </a>",
"    ]. This has led to the left lower quadrant being the preferred site of entry. By contrast, the right lower quadrant is less desirable since it may have an appendectomy scar or a cecum filled with gas due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    . If the left lower quadrant is chosen, it is helpful to have the patient roll slightly to his left to permit pooling of fluid in that area.",
"   </p>",
"   <p>",
"    The anterior superior iliac spine should be located and a site is chosen two fingerbreadths (3 cm) medial and two fingerbreadths (3 cm) cephalad to this landmark (",
"    <a class=\"graphic graphic_figure graphicRef59687 \" href=\"UTD.htm?28/46/29423\">",
"     figure 1",
"    </a>",
"    ). In the massively obese, it may be more difficult to find this landmark. It is useful to confirm dullness to percussion, to confirm that the spleen is not palpable, and that there are no surgical scars within several centimeters of the intended entry site. Ultrasound can be used to further confirm the presence of fluid and the absence of the spleen within range of the needle.",
"   </p>",
"   <p>",
"    We place an \"X\" using an ink pen at the chosen site and then make four quadrant marks at positions 12, 3, 6, and 9 o'clock, a few centimeters from the central \"X\". We sterilize the skin at and around the \"X\" and erase it with iodine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (see below). The original position of the \"X\" can be recognized at the center of the four quadrant marks. If a drape with a hole in it is used, the marks should be placed such that they are visible through the hole. The sterilization should not be so extensive that it erases all of the marks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673769\">",
"    <span class=\"h2\">",
"     Needle entry sites to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior epigastric artery traces from a point just lateral to the pubic tubercle (which is 2 to 3 cm lateral to the symphysis pubis), cephalad within the rectus sheath (",
"    <a class=\"graphic graphic_figure graphicRef59687 \" href=\"UTD.htm?28/46/29423\">",
"     figure 1",
"    </a>",
"    ). This artery can be 3 mm in diameter and can bleed massively if punctured with a large-caliber needle. Thus, this site should be specifically avoided. As noted above, areas near surgical scars should be avoided. Visible veins should also be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673776\">",
"    <span class=\"h1\">",
"     CHOICE OF NEEDLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the needle depends upon whether a diagnostic or therapeutic paracentesis is planned. As a general rule, the narrowest needle should be used to minimize complications in the event that a blood vessel or the bowel is entered by the needle. A diagnostic paracentesis can be performed in a lean patient with a 1 or 1.5 inch 22 gauge needle, while a 3.5 inch 22 gauge \"spinal\" needle can be used for diagnostic paracentesis in an obese patient.",
"   </p>",
"   <p>",
"    The effort to minimize accidental needle punctures in medical personnel has removed some of the most useful needles from the market. The functional length of the remaining needles is shortened by the guard that is frequently positioned at the hub of the needle. Clinicians should ask for the needles that they need from their clinic or hospital supply personnel.",
"   </p>",
"   <p>",
"    We specifically avoid plastic-sheathed needles. When these needles are used with a Z-track technique (see",
"    <a class=\"local\" href=\"#H337673798\">",
"     'Z-track'",
"    </a>",
"    below), there is a danger of shaving off part of the sheath into the abdominal wall or abdomen if the sharp inner component is reintroduced after it is initially withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/10\">",
"     10",
"    </a>",
"    ]. Retrieval of the plastic sheath could require laparotomy or laparoscopy, neither of which is well tolerated in patients with advanced liver disease.",
"   </p>",
"   <p>",
"    Single-hole metal needles are safest for diagnostic paracentesis. Single-hole or multiple-hole, two-piece metal needles are safest and fastest for therapeutic paracentesis (see below). The metal can be made very thin, thereby minimizing the diameter of the needle. Plastic needle sheaths are rather large in diameter and thus have the potential to create larger holes in vessels or bowel that they enter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673784\">",
"    <span class=\"h1\">",
"     TECHNIQUE OF PARACENTESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673791\">",
"    <span class=\"h2\">",
"     Diagnostic paracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After consent is obtained, the supplies have been assembled (",
"    <a class=\"graphic graphic_table graphicRef73987 \" href=\"UTD.htm?33/45/34523\">",
"     table 2",
"    </a>",
"    ), and fluid has been confirmed by physical examination or ultrasound of the selected site for the paracentesis, the operator is ready to perform the paracentesis. In teaching settings, it is useful to invite interested trainees to observe the procedure. An assistant is usually needed to help the operator once the operator puts on sterile gloves. The assistant can be a trainee, nurse, or other suitably trained clinical staff.",
"   </p>",
"   <p>",
"    No randomized trials of the exact technique of paracentesis have been performed. We have found the following approach has essentially never led to contamination of cultures in the decades we have used it.",
"   </p>",
"   <p>",
"    Wearing nonsterile gloves, we wipe the top of each of the blood culture bottle with an alcohol wipe and leave the wipe on the bottle top to attempt to maintain sterility during the performance of the procedure. The selected needle entry site is cleansed with iodine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    solution using widening circular motions starting at the \"X\" and with the operator wearing nonsterile gloves. The author uses three iodine-soaked 4x4 inch gauze sponges or three iodine swabs or three of the chlorhexidine applying devices. A drape is not necessary for this clean, but not truly sterile procedure.",
"   </p>",
"   <p>",
"    We then put on sterile gloves and draw up a 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    solution into a 3 to 5 mL syringe with the help of the assistant, who has wiped the lidocaine",
"    <span class=\"nowrap\">",
"     plastic/rubber",
"    </span>",
"    bottle top with an alcohol wipe. Sterility of the bottle top cannot be assumed without wiping it (",
"    <a class=\"graphic graphic_figure graphicRef60064 \" href=\"UTD.htm?9/51/10032\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Narrow 25 to 27 gauge needles can be difficult to find and may be available only on a tuberculin syringe that has only a 1 mL capacity. If this is the only available \"skin\" needle and it is not removable from the syringe, it can be used to draw up 1 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . However, the ideal \"skin\" needle is a 1.5 inch and 25 gauge, which is usually sufficiently thin and long to deliver anesthetic throughout the intended paracentesis track, except in the obese patient.",
"   </p>",
"   <p>",
"    If a 25 to 27 gauge needle is available separately, an 18 gauge needle can be used to draw up the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    on a 3 to 5 mL anesthesia syringe. That needle can then be removed and the narrow needle placed on the syringe. However, most 25 to 27 gauge needles are short, and another needle is usually needed to anesthetize the soft tissue. A 22 gauge 1.5 inch or 3.5 inch needle may be needed to anesthetize the soft tissue all the way to the fluid.",
"   </p>",
"   <p>",
"    The skin can then be anesthetized, raising a wheal with a small amount of anesthetic, approaching the chosen entry site tangentially with the needle. Once the wheal has been raised, the needle is withdrawn and placed at the entry site perpendicular to the curve of the abdominal wall. The remainder of the 1 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    in the tuberculin syringe can be delivered into the skin and underlying tissue. Then the 3 to 5 mL syringe full of anesthetic, with a 22 gauge 1.5 or 3.5 (in the obese patient) inch needle attached, can be used to anesthetize the entire soft tissue track to the fluid using a Z-track as described below. The needle that is used to obtain the fluid should follow the same pathway that is anesthetized. An effort should be made to reach the fluid with the anesthetic syringe and needle to confirm the presence of fluid and the depth of penetration needed to reach the ascites. The anesthetic should be injected into the same route planned for removal of the fluid in order to minimize pain, especially if a larger bore needle is used to obtain the fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673798\">",
"    <span class=\"h2\">",
"     Z-track",
"    </span>",
"    &nbsp;&mdash;&nbsp;The longer needle is inserted using a Z-track technique. The Z-track creates a non-linear pathway between the skin and the ascitic fluid, thereby helping to minimize the chance of an ascitic fluid leak.",
"   </p>",
"   <p>",
"    The proper approach to creating a Z-track has been a source of confusion. The Z-track should be created by pulling the skin downward with one hand while incrementally inserting the needle with the other hand. A gauze pad (2x2 or 4x4) is helpful to hold in the non-dominant hand and apply it to the abdominal wall to permit more traction on the abdominal wall, especially when it is wet from the cleansing solution. Sterility is optimized if the solution has dried by the time the skin is touched. The operator must be able to maneuver the syringe with one (the dominant) hand, stabilizing the outer component with the thumb and a few fingers, while pulling on the plunger of the syringe with a few fingers of the same hand (",
"    <a class=\"graphic graphic_figure graphicRef76099 \" href=\"UTD.htm?7/16/7424\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Novice operators often find this technique difficult initially and regularly pull the nondominant hand from the abdominal wall in order to use both hands to maneuver the syringe and plunger. This defeats the purpose of the Z-track. The hand on the abdominal wall should not be moved until the needle enters the fluid.",
"   </p>",
"   <p>",
"    The needle and attached syringe are inserted in 5 mm increments. Then the plunger should be pulled back a few millimeters to see if any blood is aspirated. If no blood is evident, a small amount of anesthetic is injected. Then the needle should be inserted 5 more millimeters, aspirated, then more anesthetic injected. This process is continued until the needle enters the fluid.",
"   </p>",
"   <p>",
"    Aspiration should be intermittent, not continuous. Continuous aspiration may pull bowel or omentum onto the needle tip as soon as it enters the peritoneal cavity and give the false impression that there is no fluid present when no fluid enters the needle and syringe. Releasing the suction on the syringe plunger may allow the bowel or omentum to float away and permit flow of fluid into the needle and syringe. The aspiration of yellow (or other colored) fluid into the syringe tells the operator that the peritoneal cavity has been entered.",
"   </p>",
"   <p>",
"    The hand that is on the abdominal wall can then be removed to assist with further maneuvers. The depth of entry of the needle must be stabilized so that it does not pull out of the peritoneal cavity. If the skin has been properly held on the abdominal wall during needle insertion, the needle will \"cock up\" when the syringe is removed from it. Fluid should be dripping from the hub of the needle. This proves that the needle is still in good position.",
"   </p>",
"   <p>",
"    During laparoscopy, we have seen the peritoneum \"tent\" over the needle as the needle is pushed into the abdomen. The parietal peritoneum is highly elastic and may tent a few centimeters before it is pierced. This tenting frequently explains the myth of the \"dry tap.\" When fluid is clearly present by examination and imaging, it should be able to be sampled if the needle is long enough to reach it, the needle entry site is well chosen, and the patient is positioned to allow the fluid to pool at the entry site. From the outside, the operator cannot see this tenting and may misinterpret the absence of fluid entering the syringe, despite a deep needle penetration, as a \"dry tap.\" The peritoneum may simply be tenting over the needle. Turning the needle 90 degrees or more may allow it to pierce the peritoneum and allow fluid to flow into the syringe.",
"   </p>",
"   <p>",
"    Frequently, when there is not much fluid present, it can be rather difficult to obtain a free flow of fluid. This is because the bowel or omentum is blocking the fluid entry into the needle. Multiple hole needles (used essentially exclusively for therapeutic paracentesis) help prevent this problem; when the end hole is blocked, the side holes still permit flow of fluid.",
"   </p>",
"   <p>",
"    There is a common misconception that a poor or sporadic flow of fluid means that the fluid is loculated. We have encountered true loculation infrequently in more than 35 years of performing paracenteses. Loculated fluid is typically encountered in the setting of peritoneal carcinomatosis with accumulating malignant adhesions or bowel rupture with surgical peritonitis and adhesions.",
"   </p>",
"   <p>",
"    By contrast, loculation essentially never happens in the setting of cirrhosis or heart failure with ascites. Spontaneous bacterial infection of the fluid usually does not lead to adhesions or loculations, unless the infection was detected and treated late in its course or not treated at all prior to autopsy. We have seen many autopsies of patients who had SBP that was detected and treated during that hospitalization; usually the peritoneum is normal or has only a fibrinous exudate but no adhesions or loculations.",
"   </p>",
"   <p>",
"    Sometimes there is a flow of a few drops of fluid, and then the flow ceases. This may be due to a narrow plane of fluid, with bowel or omentum occlusion of the needle tip. The patient can be slowly and gently repositioned to pool more fluid in the vicinity of the needle. This will usually reestablish the flow of fluid. In some cases, the operator has inadvertently allowed the needle tip to pull out of the peritoneal cavity. The needle can be inserted further in an attempt to reestablish the flow of fluid. A stable angle and depth of penetration of the needle are crucial to a successful paracentesis. Nervous, shaking operators frequently bounce the needle in and out of the peritoneal cavity. Patience and persistence are the keys to successful paracentesis. Impatient operators give up too easily and claim that there was a \"dry tap.\"",
"   </p>",
"   <p>",
"    If stable, deeper needle insertion does not lead to a free flow of fluid, the needle depth and angle can be stabilized with one hand while the other hand removes the syringe from the needle to see if fluid will drip from the needle hub, as is done during a lumbar puncture. Enough fluid can be obtained by this method to send for a cell count and differential at the minimum. Laboratories usually claim to require a minimum of 1 mL for cell count and differential, but far less volume is actually required. It takes only approximately 10 microliters to fill a manual hemocytometer well and a few microliters to be spread on a slide for the differential. If only a few drops of fluid are obtained, they should be placed into a purple top tube and sent for cell count and differential, informing the laboratory that there is some fluid in the tube, even though there is not enough to be easily visible. Fluid can be dripped into the purple top tube after the assistant has removed its top and holds it to catch the dripping fluid. More fluid can be obtained for other tests as needed if the operator is patient.",
"   </p>",
"   <p>",
"    A larger syringe can be attached to the needle that is dripping fluid freely, and the desired quantity of fluid can be removed, usually approximately 25 mL total, if a cell count, differential, chemical testing, and bacterial cultures are desired. We remove approximately 5 mL with a 5 mL syringe initially. It is easier to get a better \"feel\" for the ease of fluid removal and to see the fluid enter the syringe using a smaller syringe rather than a larger syringe. The syringe is then removed from the needle carefully to avoid pulling the needle tip out of the peritoneal cavity. That syringe is handed to the assistant, who is wearing nonsterile gloves. An 18 to 22 gauge needle is attached to that syringe by the assistant, and 1 to 2 mL of fluid are injected into the glass tube containing the anticoagulant; this tube usually has a purple top. If the fluid is allowed to clot prior to exposure to the anticoagulant, an accurate cell count cannot be performed. This is why the purple top tube is injected first. The remainder of the fluid in the 5 mL syringe is injected into the tube that contains no anticoagulant (usually a red top tube for chemical analyses).",
"   </p>",
"   <p>",
"    If cultures or other tests are desired, a 20 mL syringe is connected to the needle that is in the abdominal wall, and the syringe is filled with ascitic fluid. This fluid is used to inoculate the blood culture bottles. The amount of fluid placed into the bottle is similar to the amount of blood that would be injected, usually 10 mL per bottle. The assistant removes the alcohol wipe from the bottle top, and a new (18 to 22 gauge) needle is attached to the syringe to inoculate the bottles (ie, 10 mL into an aerobic and 10 mL into an anaerobic bottle). A single needle can be used to inoculate multiple bottles. The author has inoculated up to 20 culture bottles (for research purposes) with the same needle without contamination.",
"   </p>",
"   <p>",
"    A needle that has passed through the skin should",
"    <strong>",
"     not",
"    </strong>",
"    be used to inoculate the bottles. The operator should be careful not to inject any air bubbles into the bottles.",
"   </p>",
"   <p>",
"    Multiple syringes of fluid or a 60 mL syringe can be used instead of a single 20 mL syringe if multiple miscellaneous tests are desired. As an example, we send 50 mL for cytology and 50 mL for smear and culture for tuberculosis as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/16\">",
"     16",
"    </a>",
"    ]. The exact details of these unusual tests should be coordinated with the local laboratory. Some laboratories want the cytology fluid delivered immediately in a syringe or sterile cup. Others want it mixed with fixative.",
"   </p>",
"   <p>",
"    Once it has been determined that no further fluid is needed, the needle should removed in one rapid withdrawal motion. We have found that it is helpful to distract the patient by asking them to cough as the needle is removed. The cough seems to prevent the patient from sensing pain during removal of the needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673805\">",
"    <span class=\"h2\">",
"     Therapeutic paracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A therapeutic paracentesis is performed similar to the technique above for diagnostic paracentesis, except that it usually involves a 15 or 16 gauge needle to remove the bulk of the fluid. These larger needles require a #11 blade scalpel nick in the skin to permit insertion of the needle. This tiny nick should be barely long enough to permit the entry of the needle. The larger the nick, the higher the likelihood of a post-paracentesis leak. A large volume paracentesis has been defined as &gt;5 liters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diagnostic portion of the fluid can either be obtained with the smaller bore needle or the larger bore needle. The minimal amount of testing of the fluid removed for therapeutic purposes includes a cell count and differential; this test can lead to the detection of ascitic fluid infection at an early stage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with tense ascites should have enough fluid removed to relieve the intra-abdominal pressure to minimize the chance of a leak of ascitic fluid. If a patient is known to have refractory ascites, the removal of as much fluid as possible will extend the interval to the next paracentesis. If a patient's diuretic-responsiveness is not known, the removal of approximately 5 liters is enough to reduce the intra-abdominal pressure. A sodium-restricted diet and diuretics are used to further reduce the amount of fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Caldwell needle (Kimberly-Clark Quick-Tap Paracentesis Tray&trade;) has a sharp inner trocar and a blunt outer metal cannula with side holes to permit withdrawal of fluid if the end hole is occluded by bowel or omentum. This needle comes in 15 and 18 gauge and is made in 2.25, 3.25, and 4.75 inch lengths. The 3.25 inch length is the most commonly used. The 15 gauge version is better for therapeutic paracentesis.",
"   </p>",
"   <p>",
"    Vacuum bottles should be used to speed removal of fluid. These are available in 1 or 2 liter sizes. If an 8 liter paracentesis is anticipated, 4 to 8 of these bottles should be available at the bedside. Using a 60 mL syringe with no vacuum bottles is too slow and is a last resort.",
"   </p>",
"   <p>",
"    The semirigid tubing (available in the Argyle&trade; Brand Turkel&trade; Safety Paracentesis Tray, CardinalHealth Inc. and in the Kimberly-Clark Quick-Tap Paracentesis Tray) that connects the abdominal needle to the vacuum bottles should have a 16 gauge needle at one end and a luer lock at the other. Once a large bore needle is in the peritoneal cavity, the diagnostic testing has been obtained, and the metal cover over the input diaphragm of the vacuum bottle has been removed by the assistant, the semirigid tubing is connected by luer lock to the hub of the needle that is in the abdomen, the needle that is at the other end of the tubing is inserted into the soft diaphragm of the vacuum bottle, and fluid is allowed to flow.",
"   </p>",
"   <p>",
"    With abdomens full enough to permit the removal of 8 to 10 liters of fluid, flow is usually brisk for several liters. As the fluid is depleted, the bowel and omentum are more likely to occlude the needle hole(s) and slow or stop the flow of fluid. If the flow slows, the patient can be slowly and gently repositioned to pool fluid at the needle site. Some patients who have had many taps spontaneously press on the contralateral side of the abdomen with one or both hands to push the fluid toward the needle to maximize fluid removal. The more fluid removed with each paracentesis, the longer the interval between procedures. Either an assistant or the patient can press the abdomen to maximize the amount of fluid removed, depending upon patient preference.",
"   </p>",
"   <p>",
"    Only 8 liters of fluid should accumulate in approximately two weeks, even if there is no urine sodium excretion and if the patient is following the 2000 mg sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/2\">",
"     2",
"    </a>",
"    ]. We have observed up to 10 kg of weight gain in three days if the patient is consuming a large amount of salt. Patients who require more than 8 liters every two weeks should be instructed on dietary compliance to reduce the amount of fluid removed. Patients who undergo many large volume paracenteses lose kilograms of protein and develop severe muscle wasting. Alternatives options should be considered in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232498\">",
"    <span class=\"h2\">",
"     Colloid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for colloid replacement after a therapeutic paracentesis remains controversial. Our approach is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\", section on 'Colloid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673812\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, serious complications from abdominal paracentesis are uncommon, but a number have been described (",
"    <a class=\"graphic graphic_table graphicRef54050 \" href=\"UTD.htm?27/1/27675\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232530\">",
"    <span class=\"h2\">",
"     Ascitic fluid leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication is an ascitic fluid leak, which occurred in 5 percent of patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/10\">",
"     10",
"    </a>",
"    ]. Leaks typically arise when a Z-track has not been performed properly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a large bore cannula has been used, such as a plastic-sheathed needle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a large skin incision has been created. We have rarely encountered a leak using the technique described above.",
"   </p>",
"   <p>",
"    When a leak occurs, placing an ostomy bag over the leak site allows quantitation of the amount of fluid that is leaking. Placing gauze dressings over the site usually leads to rapid soaking of the dressings, rapid dressing changes, and maceration of the skin. Usually the amount of fluid decreases over a period of a few days if the patient is diuretic-sensitive. If the fluid is refractory, another therapeutic paracentesis may need to be performed (using proper technique) to stop the leak. Cellulitis may develop in the skin near the leak if it is prolonged. Retrograde infection of the ascitic fluid is exceedingly rare. If there is a large scalpel incision at the site, it can be sutured. However, the fluid may then dissect into the soft tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232537\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from an artery or vein that is impaled by the needle can be severe and potentially fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/10\">",
"     10",
"    </a>",
"    ]. An external figure-of-eight suture can be placed surrounding the needle entry site if the inferior epigastric artery is bleeding. Rarely, a laparotomy is required to control the hemorrhage. The risk of serious bleeding appears to be higher if renal failure is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with primary fibrinolysis may develop three-dimensional hematomas and require anti-fibrinolytic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232544\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is rare unless the bowel is entered by the paracentesis needle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232551\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death due to paracentesis is exceedingly rare (zero in most series) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In the two largest series, there were a total of nine deaths out of 5244 procedures (mortality rate 0.16 to 0.39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15560/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Eight of the deaths were due to bleeding, while one was due to infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/40/16002?source=see_link\">",
"       \"Patient information: Fluid in the belly (ascites) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337673819\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal paracentesis is a simple bedside or clinic procedure that provides useful information regarding the cause of ascites and the presence or absence of infection.",
"     </li>",
"     <li>",
"      A diagnostic paracentesis is performed only for testing. A therapeutic paracentesis is performed to reduce intra-abdominal pressure and to treat some patients with refractory ascites. Ascitic fluid analysis and the differential diagnosis of ascites are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"       \"Evaluation of adults with ascites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinically apparent disseminated intravascular coagulation and primary fibrinolysis are contraindications to paracentesis. (See",
"      <a class=\"local\" href=\"#H337673748\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic and therapeutic paracenteses can be performed safely despite coagulation abnormalities. There are no data-supported cut-offs beyond which the procedure should be avoided. Thus, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      giving prophylactic transfusion of blood products to target an arbitrary coagulation parameter (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H98542919\">",
"       'Coagulopathy is not an absolute contraindication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for cell count and differential should be performed on all specimens, even scheduled therapeutic paracenteses.",
"     </li>",
"     <li>",
"      Proper Z-track technique minimizes the chance of an ascitic fluid leak, the most common complication of paracentesis. Other complications are much less common. (See",
"      <a class=\"local\" href=\"#H337673812\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran&rsquo;s Gastrointestinal and Liver Diseases, 8th edition, Feldman M, Friedman L, Brandt LJ (Eds), Elsevier, 2010. p.1517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/2\">",
"      Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/3\">",
"      Soriano G, Castellote J, Alvarez C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010; 52:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/4\">",
"      Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/5\">",
"      Runyon BA, Hoefs JC, Canawati HN. Polymicrobial bacterascites. A unique entity in the spectrum of infected ascitic fluid. Arch Intern Med 1986; 146:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/6\">",
"      Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986; 146:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/7\">",
"      McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/8\">",
"      Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/9\">",
"      Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/10\">",
"      De Gottardi A, Th&eacute;venot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/11\">",
"      Yeon JE, Kwon MJ, Hyung LJ, et al. Effect of fresh frozen plasma (FFP) transfusion on prothrombin time (PT) and bleeding control in patients with chronic liver disease. Hepatology 2010; 52:908A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/12\">",
"      Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA 2008; 299:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/13\">",
"      Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/14\">",
"      Silk AW, McTigue KM. Reexamining the physical examination for obese patients. JAMA 2011; 305:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/15\">",
"      Sakai H, Sheer TA, Mendler MH, Runyon BA. Choosing the location for non-image guided abdominal paracentesis. Liver Int 2005; 25:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15560/abstract/16\">",
"      Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8:1104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16203 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-D41C5C4F74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15560=[""].join("\n");
var outline_f15_12_15560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H337673819\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673727\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673734\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98542912\">",
"      IMPORTANCE OF NOT DELAYING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673748\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98542919\">",
"      Coagulopathy is not an absolute contraindication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98543447\">",
"      WHO SHOULD PERFORM PARACENTESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673755\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673762\">",
"      PATIENT POSITION AND NEEDLE ENTRY SITE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H337673769\">",
"      Needle entry sites to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673776\">",
"      CHOICE OF NEEDLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673784\">",
"      TECHNIQUE OF PARACENTESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H337673791\">",
"      Diagnostic paracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H337673798\">",
"      Z-track",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H337673805\">",
"      Therapeutic paracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232498\">",
"      Colloid replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673812\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232530\">",
"      Ascitic fluid leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232537\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232544\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232551\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H337673819\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/16203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16203|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/46/29423\" title=\"figure 1\">",
"      Abdominal paracentesis sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/51/10032\" title=\"figure 2\">",
"      Diagnostic paracentesis needles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/16/7424\" title=\"figure 3\">",
"      Z-track technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/54/9067\" title=\"table 1\">",
"      Indications for abdominal paracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/45/34523\" title=\"table 2\">",
"      Paracentesis checklist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/1/27675\" title=\"table 3\">",
"      Complications of abdominal paracentesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/40/16002?source=related_link\">",
"      Patient information: Fluid in the belly (ascites) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15561="Date rape: Identification and management";
var content_f15_12_15561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Date rape: Identification and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Constance M Wiemann, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Samantha D Harrykissoon, JD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Vaughn I Rickert, PsyD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15561/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/12/15561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35318919\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and management of date rape will be discussed here. The epidemiology, risk factors, and prevention of date rape; sexual abuse; and the evaluation and management of sexual assault are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link\">",
"     \"Date rape: Risk factors and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11510?source=see_link\">",
"     \"Management and sequelae of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116831721\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    Sexual assault &ndash; Sexual assault is an inclusive term that refers to any form of forced or inappropriate unwanted sexual contact ranging from forced touching or kissing to verbally or physically coerced vaginal, oral, or anal penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This includes situations in which the victim is unable to consent because of intoxication, inability to understand the consequences, misperceptions because of age, or other incapacities.",
"   </p>",
"   <p>",
"    Rape &ndash; The legal definition of rape varies from state to state [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/4\">",
"     4",
"    </a>",
"    ]. It generally encompasses nonconsensual vaginal, anal, or oral penetration that involves force or threat of force (physical or psychological), lack of consent, or inability to provide consent because of age, intoxication, or mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Rape is categorized according to the relationship between the perpetrator and the victim.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stranger rape",
"      </strong>",
"      describes nonconsensual sexual penetration between individuals who do not know each other before the sexual act [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Acquaintance rape",
"      </strong>",
"      describes nonconsensual sexual penetration between individuals who know each other in some capacity before the sexual act [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Date rape",
"      </strong>",
"      is a subset of acquaintance rape in which nonconsensual sexual penetration occurs between two people who are in a romantic relationship [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/7\">",
"       7",
"      </a>",
"      ]. Date rape can occur when the victim is alert and rational, irrational, semiconscious, or unable to respond due to alcohol or other drug use. Verbal coercion, threats or use of physical force, or the use of alcohol or illicit drugs may occur as precipitating events.",
"      <br/>",
"      <br/>",
"      In many cases, date rape occurs within the context of a heterosexual dating relationship, with the male as perpetrator and the female as the victim. Same gender and female to male sexual violence also occur in dating relationships [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/8\">",
"       8",
"      </a>",
"      ]. However, because these types of dating violence are not well studied, this topic will focus on heterosexual dating violence with male perpetrators and female victims.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21895543\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent and young adult women (16 to 24 years of age) are more likely to be victims of sexual assault than are women in all other age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. Adolescents who have experienced a rape or attempted rape are three to four times as likely as those without this history to experience subsequent sexual assault during their college years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of rapes in adolescent and young adult females are committed by someone who is known to the victim; as many as 80 to 90 percent of rapes on college campuses are perpetrated by a date or acquaintance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Approximately one-fourth of college-age men report having used coercion during sexual contact [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of date rape is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H20956908#H20956908\">",
"     \"Date rape: Risk factors and prevention\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20957379\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for date rape (",
"    <a class=\"graphic graphic_table graphicRef75628 \" href=\"UTD.htm?11/29/11739\">",
"     table 1",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H19095695#H19095695\">",
"     \"Date rape: Risk factors and prevention\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25482454\">",
"    <span class=\"h1\">",
"     BARRIERS TO DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many victims of date rape do not disclose the rape to police, providers, parents, or friends [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. Male victims are less likely to report sexual assault than female victims [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Among female victims, adolescents are more likely to delay seeking medical care than are adult women.",
"   </p>",
"   <p>",
"    Disclosure of date rape is affected by the victim&rsquo;s belief in rape myths, attribution of blame (which may be related to the victim&rsquo;s use of alcohol), relationship with the perpetrator (eg, current partner), and the beliefs and stereotypes of the victim&rsquo;s culture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/23\">",
"     23",
"    </a>",
"    ]. Self-blame, shame, and fear of judgment, lack of information, and naivet&eacute; may prevent the victim from seeking care or disclosure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,6,20,24,25\">",
"     2,6,20,24,25",
"    </a>",
"    ]. Victims who feel betrayed or question their choices may find it difficult to confide in anyone. Delayed disclosure delays treatment and recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Victims may hold beliefs that prevent them from considering the forced sexual activity to be rape [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Many men and women believe that forced intercourse is rape only if a stranger commits the act in a violent and brutal manner, often with the use of a weapon. They also may believe that to be considered rape, the victim must have a &ldquo;good reputation&rdquo; and prior actions and behaviors that are beyond reproach. If any of these components is missing, the victim may not believe that",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    was raped&mdash;or",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    may fear that whomever",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    tells will not believe that",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    was raped. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H64192887#H64192887\">",
"     \"Date rape: Risk factors and prevention\", section on 'Other contributing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Victims also may be confused about whether the incident was forced or consensual [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. They may blame themselves for creating the context in which the unwanted sexual assault occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6,29,30\">",
"     6,29,30",
"    </a>",
"    ]. This is especially true when underage drinking or illegal drug use is involved. Perpetrators may not believe that they are culpable or that any harm was done [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/23,31\">",
"     23,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H20960515#H20960515\">",
"     \"Date rape: Risk factors and prevention\", section on 'Situational factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H19095737#H19095737\">",
"     \"Date rape: Risk factors and prevention\", section on 'Adolescent perceptions of sexual behavior'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional barriers to disclosure may include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,16,32-34\">",
"     2,16,32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased access to care (eg, lack of health insurance)",
"     </li>",
"     <li>",
"      Concern that the lack of physical harm or delay in disclosure may cause others to doubt the authenticity of the rape &nbsp;",
"     </li>",
"     <li>",
"      Lack of memory of the assault (eg, if a &ldquo;date rape drug&rdquo; was used) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H278703864#H278703864\">",
"       \"Date rape: Risk factors and prevention\", section on 'Illicit drugs'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fear about judgment by family or communities (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H49773827#H49773827\">",
"       \"Date rape: Risk factors and prevention\", section on 'Cultural considerations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Concern about lack of confidentiality",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49780578\">",
"    <span class=\"h1\">",
"     IDENTIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49780769\">",
"    <span class=\"h2\">",
"     Symptoms and sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent and young adult victims of date rape may develop symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequelae of sexual violence. These symptoms and sequelae may be the presenting complaints of victims who have not disclosed the assault. The recognition of these findings as possible manifestations of sexual assault may facilitate earlier identification of and intervention for victims of sexual violence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Psychosocial issues'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Symptoms and sequelae of sexual violence include (",
"    <a class=\"graphic graphic_table graphicRef56678 \" href=\"UTD.htm?33/27/34235\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,4,6,35-39\">",
"     2,4,6,35-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disturbances in sleep (eg, taking more than 20 minutes to fall asleep, nightmares)",
"     </li>",
"     <li>",
"      Decrease in appetite; less interest in eating",
"     </li>",
"     <li>",
"      Somatic reactions (eg, chronic pelvic pain, recurrent abdominal pain, chronic headache, multiple physical complaints)",
"     </li>",
"     <li>",
"      Depressive symptoms, particularly in the first two months after the assault (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H7#H7\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Phenomenology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suicidality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anxiety, which remains at high levels throughout the first year after the assault (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Signs of post-traumatic stress disorder (emotional numbing, diminished interest in everyday activities, detachment from others) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link&amp;anchor=H10#H10\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psychiatric or behavior problems that usually are found in the other gender (eg, eating disorders in boys or fighting in girls) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      School failure",
"     </li>",
"     <li>",
"      Decreased self-esteem, self-worth,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      confidence in their sense of judgment",
"     </li>",
"     <li>",
"      Difficulty maintaining relationships",
"     </li>",
"     <li>",
"      Sexual dysfunction (satisfaction and pleasure in sexual activities may be reduced in victims for at least a year) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6,42,43\">",
"       6,42,43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Male victims report fragility of their sense of masculinity and confusion about their sexual orientation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,44,45\">",
"       2,44,45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    History of sexual assault is associated with alcohol or substance abuse and decreased sexual negotiation skills, which may lead to lack of contraception and condom use, pregnancy, or sexually transmitted infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/46-56\">",
"     46-56",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Alcohol/substance",
"    </span>",
"    use and decreased sexual negotiation skills may be precursors to sexual victimization, consequences of sexual victimization, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/53\">",
"     53",
"    </a>",
"    ]. They also may contribute to the increased risk of revictimization. (See",
"    <a class=\"local\" href=\"#H390659439\">",
"     'Preventing revictimization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25482461\">",
"    <span class=\"h2\">",
"     Promoting disclosure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before screening for sexual assault, it is important for clinicians to be aware of the unique reporting requirements of their state and local institutions and to have a referral plan in place [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26758358\">",
"     'Reporting requirements and confidentiality'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H193713822\">",
"     'Psychosocial support'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pediatric health care provider can facilitate disclosure of date or acquaintance rape by [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishing an environment conducive to disclosure; victims of violence must feel that they are in a safe and welcoming place in order to disclose the experience; creating such an environment requires that office staff are ready and able to discuss dating violence and to provide help when it is disclosed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/58\">",
"       58",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H45125612\">",
"       'Management'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Providing anticipatory guidance and educational materials (eg, pamphlets and videotapes); this demonstrates the provider&rsquo;s sensitivity to sexual violence and willingness to discuss the occurrence of sexual aggression among dating partners (see",
"      <a class=\"local\" href=\"#H49779193\">",
"       'Resources'",
"      </a>",
"      below) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Providing general information about the prevalence of sexual assault in dating relationships; this may help a victimized patient realize that",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      is not the only person who has experienced dating violence [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Asking about dating violence, which opens the door to communication and possible help",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H619927463\">",
"    <span class=\"h3\">",
"     Asking about dating violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asking adolescent and young adult patients about the symptoms and sequelae of date rape (",
"    <a class=\"graphic graphic_table graphicRef56678 \" href=\"UTD.htm?33/27/34235\">",
"     table 2",
"    </a>",
"    ) may help to promote disclosure. Some victims may not have labeled their unwanted sexual experience as rape and therefore, may not think about disclosing it; others may be ashamed or embarrassed about the event, but willing to talk about their symptoms (eg, inability to sleep, poor appetite, etc). (See",
"    <a class=\"local\" href=\"#H49780769\">",
"     'Symptoms and sequelae'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25482454\">",
"     'Barriers to disclosure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, screening for dating violence is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/48,60\">",
"     48,60",
"    </a>",
"    ]. Those who argue against screening suggest that consistent measures for identifying at-risk groups are lacking and appropriate resources for treatment may not be available in many communities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/60\">",
"     60",
"    </a>",
"    ]. Those who support screening suggest that sexual violence is a widespread problem that affects the health of victims, that screening is an important way to overcome barriers to disclosure, and that disclosure may affect clinical management or anticipatory guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/20,48\">",
"     20,48",
"    </a>",
"    ]. Moreover, in a survey of 645 ethnically diverse adolescent and young adult women, more than 90 percent indicated that a health care provider was the most appropriate adult to ask about interpersonal violence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists recommends universal screening of women for intimate partner violence, including",
"    <span class=\"nowrap\">",
"     date/acquaintance",
"    </span>",
"    rape and has developed tools to facilitate screening [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) guidelines for the care of adolescent sexual assault victims indicate that screening for sexual victimization should be part of visits for psychosocial problems, sexuality issues, contraception or substance abuse, and health supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26758358\">",
"    <span class=\"h3\">",
"     Reporting requirements and confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legal definitions of and reporting requirements for sexual assault vary by state. Before screening for sexual assault, clinicians should be aware of the unique reporting requirements of their state and local institutions. Questions about the requirements can be answered by the state child protection agency, the district attorney&rsquo;s office,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local women&rsquo;s organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the age of the victim and state-reporting requirements, the evaluating provider may need to report the assault to child protective services even if the victim does not want to press charges [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,65\">",
"     2,65",
"    </a>",
"    ]. Reporting requirements should be communicated to the patient in the context of the patient-provider confidentiality agreement, explicitly defining the circumstances under which confidentiality is &ldquo;conditional&rdquo;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link&amp;anchor=H6#H6\">",
"     \"Confidentiality in adolescent health care\", section on 'Exceptions to confidentiality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of how to introduce the concept of conditional confidentiality follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Generally, what you say in here stays in here, but there are some exceptions. If I feel that you may hurt yourself or someone else, or that you have been abused by someone, I will need to talk to others to help make sure you get all the care you need.&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ldquo;I want you to understand that when we talk about things that have to do with sex and drugs and your feelings, it is confidential. This means that what we talk about is just between you and me and that other people, including your parents, will not find out about it unless you want them to know. One exception to this is if I am concerned someone has abused or hurt you. Another exception is if I am concerned you are at serious risk of harm or are planning to or behaving as though you may hurt yourself or someone else. In these situations, I would have to talk to other adults, but I would talk to you first so we could figure out whom we should talk to and the best way to handle it.\" [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26758530\">",
"    <span class=\"h3\">",
"     How to ask about dating violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asking about dating violence should be done without the parents present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinicians can ask direct questions about dating violence or ask a series of general open-ended questions with the intent of leading the patient to spontaneously discuss dating violence (eg, &ldquo;Tell me about your partner,&rdquo; &ldquo;How does your partner treat you?&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/48,57\">",
"     48,57",
"    </a>",
"    ]. Direct questions are more successful and are recommended by the AAP, the American College of Obstetricians and Gynecologists, and other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,48,62,67,68\">",
"     2,48,62,67,68",
"    </a>",
"    ]. Examples of how to introduce the discussion of sexual experience include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Because I want to help my patients, I ask everyone about topics that may be very sensitive or may make you uncomfortable. Some young adults come to my office having been hurt by people around them. It is important that I know these things to be able to help them out.&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ldquo;Many teens your age experience threats, name calling, uninvited touching, sex, or violence, so I ask all my teen patients about it. May I ask you a few questions?&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AAP suggests that direct questions about sexual experiences should include questions about [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age at first sexual experience",
"     </li>",
"     <li>",
"      Use of the Internet to find romantic or sexual partners",
"     </li>",
"     <li>",
"      Unwanted or forced sexual acts (eg, &ldquo;Has your partner ever forced you to have sex when you didn&rsquo;t want to?&rdquo;, &ldquo;Has your partner ever refused to practice safe sex?&rdquo;, &ldquo;Have you ever been forced to do something sexual that you didn&rsquo;t want to do?&rdquo;) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gender roles",
"     </li>",
"     <li>",
"      Relationship parameters (eg, exploitative or nonconsensual versus healthy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial evaluated the effectiveness of various screening approaches in identifying relationship violence (physical, emotional, sexual) among young women (15 to 24 years of age) attending a reproductive health clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/69\">",
"     69",
"    </a>",
"    ]. Detection was greatest with the bidirectional approach, which acknowledges the role that both partners may play in inflicting and receiving violence. These brief screening questions were well received by both patients and providers and may be useful in a variety of busy practice settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the past year:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      My partner is suspicious that I am unfaithful.",
"     </li>",
"     <li>",
"      I am suspicious that my partner is unfaithful.",
"     </li>",
"     <li>",
"      My partner forced me to have sex when I didn&rsquo;t want to.",
"     </li>",
"     <li>",
"      I forced my partner to have sex when",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      didn&rsquo;t want to.",
"     </li>",
"     <li>",
"      My partner hit, slapped, or physically hurt me on purpose.",
"     </li>",
"     <li>",
"      I hit, slapped, or physically hurt my partner on purpose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At",
"      <strong>",
"       any",
"      </strong>",
"      point in the past, including the past year:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Have you ever been slapped, hit, or otherwise physically hurt by your partner?",
"     </li>",
"     <li>",
"      Has anyone ever raped you or forced you into a sexual act?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although other instruments have been used to evaluate relationship violence in clinic settings for research purposes, they tend to be long (eg, the Conflict in Adolescent Dating Relationships Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/70\">",
"     70",
"    </a>",
"    ], the Sexual Aggression Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/71\">",
"     71",
"    </a>",
"    ]) or limited in scope (eg, the Sexual Experience Survey [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/72\">",
"     72",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H304702413\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute evaluation for sexual assault is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21899419\">",
"    <span class=\"h2\">",
"     Forensic evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual jurisdictions determine the maximal time interval in which forensic evidence may be collected; the interval typically varies from 36 hours to 1 week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/48\">",
"     48",
"    </a>",
"    ]. If the sexual assault is disclosed within a timeframe when collection of forensic evidence is feasible, and the victim wants to file charges, the victim should be advised not to wash their clothes, bathe, or shower, until they have undergone forensic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. Clothes worn during the incident should be stored in a paper bag. In some facilities, patients may have the option of freezing forensic evidence for possible use in the future if they are uncertain about filing charges at the time of presentation.",
"   </p>",
"   <p>",
"    Additional information about the collection of forensic evidence is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Forensic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45125612\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of sexual assault involves provision of psychosocial support and prevention of pregnancy, sexually transmitted infections, and revictimization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193713822\">",
"    <span class=\"h2\">",
"     Psychosocial support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents and young adults who disclose that they have been sexually assaulted benefit from the opportunity to describe the experience at a comfortable pace and in their own words; sufficient time should be provided for this conversation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,22,28\">",
"     2,22,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The health care provider&rsquo;s initial response to disclosure should be one of empathy and support [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/73\">",
"     73",
"    </a>",
"    ]. Such a reaction demonstrates respect and is critical to keeping the lines of patient-clinician communication open. The health care provider should recognize and appreciate the subjective experience from the patient&rsquo;s perspective. Acknowledging the patient&rsquo;s feelings, concerns, and fears may help to restore their belief in themselves as a normal, healthy individual. The provider can help the patient to identify individuals in the patient&rsquo;s social network who can provide additional support. However, providers must obtain permission from the patient before engaging family members or friends for support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .) Offering the patient options for treatment or support and respecting their decisions helps them to regain a sense of control over their life and to realize that they have the ability to make decisions.",
"   </p>",
"   <p>",
"    Sexual assault affects the victim&rsquo;s sense of self and their sexuality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/4\">",
"     4",
"    </a>",
"    ]. Internalized feelings of guilt, shame, betrayal, and anger can impede recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6\">",
"     6",
"    </a>",
"    ]. The victims should be told, repeatedly if necessary, that they were not responsible: Rape is never the victim&rsquo;s fault [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. Because of the potential for long-term psychological consequences, clinicians should be prepared to offer psychological support or referral for counseling (eg, to a social worker, counselor, or dating violence hotline). The provision of mental health services (eg, support groups, group therapy, individual therapy) can help to restore a sense of normalcy and provide a therapeutic environment that facilitates recovery. Awareness of community resources can facilitate timely referrals. The names of mental health professionals who are skilled in the care of sexual assault victims may be obtained by calling a sexual assault care center [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. Funding for care may be available through the",
"    <a class=\"external\" href=\"file://www.ojp.usdoj.gov/ovc/about/victimsfund.html\">",
"     Crime Victims Fund",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It may be helpful to encourage the victim to discuss the incident with a parent or other trusted adult [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. The involvement of such a support person may ensure that the victim receives support and appropriate counseling, particularly if the victim becomes depressed and lacks the initiative or ability to access help. However, it is important to respect the victim&rsquo;s decisions about who and when to tell about the assault [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20957959\">",
"    <span class=\"h2\">",
"     Medical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health concerns that must be addressed in adolescent and young adult sexual assault victims who present soon after the incident include the possibility of pregnancy, sexually transmitted infections, and physical injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. However, few adolescent victims of sexual assault seek medical care directly following the assault experience [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/65\">",
"     65",
"    </a>",
"    ]. Analysis of data from the longitudinal National Women&rsquo;s study indicates that non-white",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    injury, concern about sexually transmitted infection, and having reported the assault to authorities were associated with seeking medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adolescent and young adult victims of sexual violence are less likely to sustain physical injuries during the assault than are older adult victims [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2,12,65\">",
"     2,12,65",
"    </a>",
"    ]. Nonetheless, providers should conduct a thorough physical examination, with special focus on the genitalia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of pregnancy and sexually transmitted infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link&amp;anchor=H6#H6\">",
"     \"Emergency contraception\", section on 'Options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation and management of adult sexual assault victims\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H390659555\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of dating violence are at risk for suicidality, self-harm, and subsequent harm by the perpetrator. All victims of sexual assault should be screened for suicidal ideation and self-harm behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\", section on 'Identification of suicide risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues of personal safety should be addressed by asking if the victim is still in a relationship with the perpetrator, and identifying whether the perpetrator has access to the victim&rsquo;s car, apartment, or any other area of the victim&rsquo;s life where personal safety may be compromised. Additional information about safety assessment and formulating a safety plan is available in the",
"    <a class=\"external\" href=\"file://www.futureswithoutviolence.org/userfiles/file/Consensus.pdf\">",
"     Family Violence Prevention&rsquo;s National Consensus Guidelines on Identifying and Responding to Domestic Violence Victimization in Health Care Settings",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H390659439\">",
"    <span class=\"h2\">",
"     Preventing revictimization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing revictimization is an important aspect of the treatment of adolescent and young adult victims of date rape [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6\">",
"     6",
"    </a>",
"    ]. Adolescents who have experienced a rape or attempted rape are three to four times as likely as those without this history to experience subsequent sexual assault during their college years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Difficulty in stopping unwanted sexual contact plays a role in the cycle of sexual victimization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of date rape is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H19095744#H19095744\">",
"     \"Date rape: Risk factors and prevention\", section on 'Prevention'",
"    </a>",
"    .) Prevention of revictimization involves a special focus on helping victims to [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6,75\">",
"     6,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identify sexually aggressive partners",
"     </li>",
"     <li>",
"      Identify and avoid dangerous situations",
"     </li>",
"     <li>",
"      Be more assertive in their sexual negotiations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tasks can be particularly difficult for adolescents and young adults&mdash;the factors that contribute to the progression from normal sexual negotiation to coercive sexual activity are typical elements of adolescent and college life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. It can be difficult to balance the desire for normal",
"    <span class=\"nowrap\">",
"     adolescent/young",
"    </span>",
"    adult social interaction with the sense of heightened vulnerability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H304702475\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics suggests that victims of sexual assault be seen within one week of disclosure to ensure that counseling has been arranged and to provide assessment for sexually transmitted infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    injury healing (as indicated) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"     2",
"    </a>",
"    ]. Thereafter, the frequency of follow-up should be individualized according to patient circumstances (eg, support network, ongoing relationship with perpetrator, participation in counseling). Some patients may require frequent office visits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    provider availability by phone during the first few months after disclosure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49779193\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources related to",
"    <span class=\"nowrap\">",
"     date/acquaintance",
"    </span>",
"    rape for patients, parents, and providers are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.acog.org/~/media/departments/adolescent health care/teen care tool kit/acquaintdaterape.pdf?dmc=1&amp;ts=20120319t1525268066\">",
"       The American College of Obstetricians and Gynecologists Acquaintance and Date Rape Fact Sheet",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/features/datingviolence/\">",
"       The Centers for Disease Control and Prevention Preventing Teen Dating Violence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/violenceprevention/pdf/teendatingviolence2012-a.pdf\">",
"       The Centers for Disease Control and Prevention Understanding Teen Dating Violence Fact Sheet",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://mchlibrary.info/knowledgepaths/kp_domviolence.html\">",
"       The Maternal and Child Health Library (Georgetown University) Dating Violence Among Adolescents",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://victimsofcrime.org/help-for-crime-victims/get-help-bulletins-for-crime-victims/bulletins-for-teens/dating-violence\">",
"       The National Center for the Victims of Crime",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nsvrc.org/\">",
"       The National Sexual Violence Resource Center",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://kidshealth.org/teen/your_mind/relationships/date_rape.html\">",
"       TeensHealth from Nemours",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25482475\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Date rape is subset of acquaintance rape in which nonconsensual sexual penetration occurs between two people who are in a romantic relationship. (See",
"      <a class=\"local\" href=\"#H116831721\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Date rape occurs most often among young women between the ages of 16 and 24 years. Other risk factors for sexual assault are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef75628 \" href=\"UTD.htm?11/29/11739\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21895543\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H19095695#H19095695\">",
"       \"Date rape: Risk factors and prevention\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disclosure of date rape is often delayed due to self-blame, shame, fear of judgment, or failure to label the experience as rape. Victims of date rape may present with psychological sequelae of sexual assault (",
"      <a class=\"graphic graphic_table graphicRef56678 \" href=\"UTD.htm?33/27/34235\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25482454\">",
"       'Barriers to disclosure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H49780769\">",
"       'Symptoms and sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric health care providers can promote disclosure of sexual violence by establishing an environment conducive to disclosure, providing anticipatory guidance and educational materials about date rape and other forms of sexual coercion, and asking their patients about sexual violence. (See",
"      <a class=\"local\" href=\"#H25482461\">",
"       'Promoting disclosure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H49779193\">",
"       'Resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of date rape involves provision of psychosocial support and prevention of pregnancy, sexually transmitted infections, and revictimization. (See",
"      <a class=\"local\" href=\"#H45125612\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20957959\">",
"       'Medical issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents and young adults who disclose that they have been sexually assaulted benefit from the opportunity to describe the experience at a comfortable pace and in their own words. Acknowledging the patient&rsquo;s feelings, concerns, and fears may help to restore their belief in themselves as a normal, healthy individual. Providing them with options for treatment and respecting their decisions helps them to regain a sense of control. Patients with ongoing mental health symptoms may warrant psychologic or psychiatric referral. (See",
"      <a class=\"local\" href=\"#H193713822\">",
"       'Psychosocial support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Victims of date rape are at risk for suicidality, self-harm, and subsequent harm by the perpetrator. They should be screened for suicidal ideation and self-harm behavior and asked about an ongoing relationship with the perpetrator. (See",
"      <a class=\"local\" href=\"#H390659555\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents who have experienced a rape or attempted rape are at increased risk for subsequent sexual assault. Prevention of revictimization involves helping victims to identify sexually aggressive partners, helping victims to identify and avoid dangerous situations, and helping victims to be more assertive in their sexual negotiations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link&amp;anchor=H19095744#H19095744\">",
"       \"Date rape: Risk factors and prevention\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/1\">",
"      Young A, Grey M, Abbey A, et al. Alcohol-related sexual assault victimization among adolescents: prevalence, characteristics, and correlates. J Stud Alcohol Drugs 2008; 69:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/2\">",
"      Kaufman M, American Academy of Pediatrics Committee on Adolescence. Care of the adolescent sexual assault victim. Pediatrics 2008; 122:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/3\">",
"      Danielson CK, Holmes MM. Adolescent sexual assault: an update of the literature. Curr Opin Obstet Gynecol 2004; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     Rickert VI, Ryan O, Chacko M. Sexual assault and victimization. In: Adolescent Health Care: A practical guide, 5th ed, Neinstein LS, Gordon C, Katzman D, et al.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.1042.",
"    </li>",
"    <li>",
"     Bureau of Justice Statistics. Violence against women: Estimates from the redesigned survey. file://bjs.ojp.usdoj.gov/content/pub/pdf/FEMVIED.PDF (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/6\">",
"      Lam C, Roman B. When Granny Is the Wolf: Understanding and Approaching College-aged Female Victims of Acquaintance Rape. Psychiatry (Edgmont) 2009; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/7\">",
"      Rickert VI, Wiemann CM. Date rape among adolescents and young adults. J Pediatr Adolesc Gynecol 1998; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/8\">",
"      Porter J, Williams LM. Intimate violence among underrepresented groups on a college campus. J Interpers Violence 2011; 26:3210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/9\">",
"      Rickert VI, Vaughan RD, Wiemann CM. Adolescent dating violence and date rape. Curr Opin Obstet Gynecol 2002; 14:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/10\">",
"      Humphrey JA, White JW. Women's vulnerability to sexual assault from adolescence to young adulthood. J Adolesc Health 2000; 27:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/11\">",
"      Smith PH, White JW, Holland LJ. A longitudinal perspective on dating violence among adolescent and college-age women. Am J Public Health 2003; 93:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/12\">",
"      Peipert JF, Domagalski LR. Epidemiology of adolescent sexual assault. Obstet Gynecol 1994; 84:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/13\">",
"      Violence against women. Relevance for medical practitioners. Council on Scientific Affairs, American Medical Association. JAMA 1992; 267:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/14\">",
"      Koss MP, Gidycz CA, Wisniewski N. The scope of rape: incidence and prevalence of sexual aggression and victimization in a national sample of higher education students. J Consult Clin Psychol 1987; 55:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/15\">",
"      Ashley OS, Foshee VA. Adolescent help-seeking for dating violence: prevalence, sociodemographic correlates, and sources of help. J Adolesc Health 2005; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/16\">",
"      Nasta A, Shah B, Brahmanandam S, et al. Sexual victimization: incidence, knowledge and resource use among a population of college women. J Pediatr Adolesc Gynecol 2005; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/17\">",
"      Amstadter AB, Zinzow HM, McCauley JL, et al. Prevalence and correlates of service utilization and help seeking in a national college sample of female rape victims. J Anxiety Disord 2010; 24:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/18\">",
"      Lacey HB, Roberts R. Sexual assault on men. Int J STD AIDS 1991; 2:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/19\">",
"      Seifert SA. Substance use and sexual assault. Subst Use Misuse 1999; 34:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/20\">",
"      Rickert VI, Wiemann CM, Vaughan RD. Disclosure of date/acquaintance rape: who reports and when. J Pediatr Adolesc Gynecol 2005; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/21\">",
"      Kogan SM. Disclosing unwnated sexual experiences: results from a national sample of adolescent women. Child Abuse Negl 2004; 28:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/22\">",
"      Dunn PC, Vail-Smith K, Knight SM. What date/acquaintance rape victims tell others: a study of college student recipients of disclosure. J Am Coll Health 1999; 47:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/23\">",
"      Marx BP, Van Wie V, Gross AM. Date rape risk factors: a review and methodological critique of the literature. Aggres Violent Behav 1996; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/24\">",
"      Neville HA, Pugh AO. General and culture-specific factors influencing African American women's reporting patterns and perceived social support following sexual assault. An exploratory investigation. Violence Against Women 1997; 3:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/25\">",
"      Rickert VI, Edwards S, Harrykissoon SD, Wiemann CM. Violence in the lives of young women: clinical care and management. Curr Womens Health Rep 2001; 1:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/26\">",
"      Anderson KB, Cooper H, Okamura L. Individual differences and attitudes toward rape: a meta-analytic review. Pers Soc Psychol Bull 1997; 23:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/27\">",
"      Burt MR. Cultural myths and supports for rape. J Pers Soc Psychol 1980; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/28\">",
"      Koval JE. Violence in dating relationships. J Pediatr Health Care 1989; 3:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/29\">",
"      Muehlenhard CL, McNaughton JS. Women's beliefs about women who \"lead men on\". J Soc Clin Psychol 1988; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/30\">",
"      Canterbury RJ, Grossman SJ, Lloyd E. Drinking behaviors and lifetime incidents of date rape among high school graduates upon entering college. College Student J 1993; 27:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/31\">",
"      Muelenhard CL, Friedman DE, Thomas C. Is date rape justifiable? The effects of dating activity, who initiated, who paid, and men's attitudes toward women. Psychol Women Quarterly 1985; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/32\">",
"      Howard JA. A structural approach to sexual attitudes: interracial patterns in adolescents' judgements about sexual intimacy. Sociological Perspectives 1988; 31:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/33\">",
"      Walsh WA, Banyard VL, Moynihan MM, et al. Disclosure and service use on a college campus after an unwanted sexual experience. J Trauma Dissociation 2010; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/34\">",
"      Sable MR, Danis F, Mauzy DL, Gallagher SK. Barriers to reporting sexual assault for women and men: perspectives of college students. J Am Coll Health 2006; 55:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/35\">",
"      Ackard DM, Eisenberg ME, Neumark-Sztainer D. Long-term impact of adolescent dating violence on the behavioral and psychological health of male and female youth. J Pediatr 2007; 151:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/36\">",
"      ACOG educational bulletin. Adolescent victims of sexual assault. Number 252, October 1998. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 64:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/37\">",
"      Zinzow HM, Resnick HS, McCauley JL, et al. The role of rape tactics in risk for posttraumatic stress disorder and major depression: results from a national sample of college women. Depress Anxiety 2010; 27:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/38\">",
"      American College of Obstetricians and Gynecologists. Committee on Health Care for Underserved Women. Committee opinion no. 499: Sexual assault. Obstet Gynecol 2011; 118:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/39\">",
"      Exner-Cortens D, Eckenrode J, Rothman E. Longitudinal associations between teen dating violence victimization and adverse health outcomes. Pediatrics 2013; 131:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/40\">",
"      Olshen E, McVeigh KH, Wunsch-Hitzig RA, Rickert VI. Dating violence, sexual assault, and suicide attempts among urban teenagers. Arch Pediatr Adolesc Med 2007; 161:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/41\">",
"      Shrier LA, Pierce JD, Emans SJ, DuRant RH. Gender differences in risk behaviors associated with forced or pressured sex. Arch Pediatr Adolesc Med 1998; 152:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/42\">",
"      van Berlo W, Ensink B. Problems with sexuality after sexual assault. Annu Rev Sex Res 2000; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/43\">",
"      Becker JV, Skinner LJ, Abel GG, et al. Sexual problems of sexual assault survivors. Women Health 1984; 9:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/44\">",
"      Myers MF. Men sexually assaulted as adults and sexually abused as boys. Arch Sex Behav 1989; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/45\">",
"      Rentoul L, Appleboom N. Understanding the psychological impact of rape and serious sexual assault of men: a literature review. J Psychiatr Ment Health Nurs 1997; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/46\">",
"      Blythe MJ, Fortenberry JD, Temkit M, et al. Incidence and correlates of unwanted sex in relationships of middle and late adolescent women. Arch Pediatr Adolesc Med 2006; 160:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/47\">",
"      Silverman JG, Raj A, Mucci LA, Hathaway JE. Dating violence against adolescent girls and associated substance use, unhealthy weight control, sexual risk behavior, pregnancy, and suicidality. JAMA 2001; 286:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/48\">",
"      Carolyn Olson E, Rickert VI, Davidson LL. Identifying and supporting young women experiencing dating violence: what health practitioners should be doing NOW. J Pediatr Adolesc Gynecol 2004; 17:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/49\">",
"      Diaz A, Simantov E, Rickert VI. Effect of abuse on health: results of a national survey. Arch Pediatr Adolesc Med 2002; 156:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/50\">",
"      Rickert VI, Wiemann CM, Harrykissoon SD, et al. The relationship among demographics, reproductive characteristics, and intimate partner violence. Am J Obstet Gynecol 2002; 187:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/51\">",
"      Basile KC, Black MC, Simon TR, et al. The association between self-reported lifetime history of forced sexual intercourse and recent health-risk behaviors: findings from the 2003 National Youth Risk Behavior Survey. J Adolesc Health 2006; 39:752.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/52\">",
"      Decker MR, Silverman JG, Raj A. Dating violence and sexually transmitted disease/HIV testing and diagnosis among adolescent females. Pediatrics 2005; 116:e272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/53\">",
"      Champion HL, Foley KL, DuRant RH, et al. Adolescent sexual victimization, use of alcohol and other substances, and other health risk behaviors. J Adolesc Health 2004; 35:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/54\">",
"      Hanson MJ. Health behavior in adolescent women reporting and not reporting intimate partner violence. J Obstet Gynecol Neonatal Nurs 2010; 39:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/55\">",
"      Testa M, Hoffman JH, Livingston JA. Alcohol and sexual risk behaviors as mediators of the sexual victimization-revictimization relationship. J Consult Clin Psychol 2010; 78:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/56\">",
"      Howard DE, Wang MQ. Psychosocial correlates of U.S. adolescents who report a history of forced sexual intercourse. J Adolesc Health 2005; 36:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/57\">",
"      Lin AJ, Raymond M, Catallozzi M, et al. Relationship violence in adolescence. Adolesc Med State Art Rev 2007; 18:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/58\">",
"      Stevens L. 'A practical approach to gender-based violence: a programme guide for health care providers and managers' developed by the UN Population Fund. Int J Gynaecol Obstet 2002; 78 Suppl 1:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/59\">",
"      Finkelson L, Oswalt R. College date rape: incidence and reporting. Psychol Rep 1995; 77:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/60\">",
"      Omar H. Screening for dating violence: should we screen or not? J Pediatr Adolesc Gynecol 2004; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/61\">",
"      Zeitler MS, Paine AD, Breitbart V, et al. Attitudes about intimate partner violence screening among an ethnically diverse sample of young women. J Adolesc Health 2006; 39:119.e1.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Screening tools--Sexual assault. file://www.acog.org/departments/dept_notice.cfm?recno=17&amp;bulletin=1477 (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/63\">",
"      ACOG Committee opinion no. 554: reproductive and sexual coercion. Obstet Gynecol 2013; 121:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/64\">",
"      ACOG Committee Opinion No. 518: Intimate partner violence. Obstet Gynecol 2012; 119:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/65\">",
"      Muram D, Hostetler BR, Jones CE, Speck PM. Adolescent victims of sexual assault. J Adolesc Health 1995; 17:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/66\">",
"      Ford CA, Millstein SG, Halpern-Felsher BL, Irwin CE Jr. Influence of physician confidentiality assurances on adolescents' willingness to disclose information and seek future health care. A randomized controlled trial. JAMA 1997; 278:1029.",
"     </a>",
"    </li>",
"    <li>",
"     Identifying and responding to domestic violence: Consensus recommendation for child and adolescent health. file://www.futureswithoutviolence.org/userfiles/file/HealthCare/pediatric.pdf (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     National consensus guidelines on identifying and responding to domestic violence victimization in health care settings. file://www.futureswithoutviolence.org/userfiles/file/Consensus.pdf (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/69\">",
"      Rickert VI, Davison LL, Breitbart V, et al. A randomized trial of screening for relationship violence in young women. J Adolesc Health 2009; 45:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/70\">",
"      Wolfe DA, Scott K, Reitzel-Jaffe D, et al. Development and validation of the Conflict in Adolescent Dating Relationships Inventory. Psychol Assess 2001; 13:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/71\">",
"      Muelenhard CL, Linton MA. Date rape and sexual aggression in dating situations: incidence and risk factors. J Counsel Psychol 1987; 34:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/72\">",
"      Koss MP, Oros CJ. Sexual Experiences Survey: a research instrument investigating sexual aggression and victimization. J Consult Clin Psychol 1982; 50:455.",
"     </a>",
"    </li>",
"    <li>",
"     Ledray LE. Responding to the needs of rape victims. In: Rape and sexual assault II, Burgess A (Ed), Garland Publishing, New York 1988. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/74\">",
"      Hanson RF, Davis JL, Resnick HS, et al. Predictors of medical examinations following child and adolescent rapes in a national sample of women. Child Maltreat 2001; 6:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/75\">",
"      Soler-Baillo JM, Marx BP, Sloan DM. The psychophysiological correlates of risk recognition among victims and non-victims of sexual assault. Behav Res Ther 2005; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15561/abstract/76\">",
"      Adams-Curtis LE, Forbes GB. College women's experiences of sexual coercion: a review of cultural, perpetrator, victim, and situational variables. Trauma Violence Abuse 2004; 5:91.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14314 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-BE0DD41560-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15561=[""].join("\n");
var outline_f15_12_15561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25482475\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35318919\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116831721\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21895543\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20957379\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25482454\">",
"      BARRIERS TO DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49780578\">",
"      IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49780769\">",
"      Symptoms and sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25482461\">",
"      Promoting disclosure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H619927463\">",
"      - Asking about dating violence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26758358\">",
"      - Reporting requirements and confidentiality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26758530\">",
"      - How to ask about dating violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H304702413\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21899419\">",
"      Forensic evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45125612\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193713822\">",
"      Psychosocial support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20957959\">",
"      Medical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H390659555\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H390659439\">",
"      Preventing revictimization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H304702475\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49779193\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25482475\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/29/11739\" title=\"table 1\">",
"      Risk factors for date rape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/27/34235\" title=\"table 2\">",
"      Symptoms and sequelae of date rape",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=related_link\">",
"      Date rape: Risk factors and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11510?source=related_link\">",
"      Management and sequelae of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15562="Echocardiographic recognition of cardiomyopathies";
var content_f15_12_15562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic recognition of cardiomyopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/12/15562/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/12/15562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15920411\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the classification of the 1995 World Health",
"    <span class=\"nowrap\">",
"     Organization/International",
"    </span>",
"    Society and Federation of Cardiology",
"    <span class=\"nowrap\">",
"     (WHO/ISFC)",
"    </span>",
"    Task Force on the Definition and Classification of Cardiomyopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/1\">",
"     1",
"    </a>",
"    ], there are five major types of cardiomyopathy (ie, diseases of the myocardium associated with cardiac dysfunction) that can be appreciated and differentiated by echocardiography. These conditions can affect either ventricle but are most often recognized when they involve the left ventricle. The 2006 American Heart Association (AHA) and 2008 European Society of Cardiology (ESC) classification systems include these five types but differ from the earlier",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    classification in emphasizing the distinction between",
"    <span class=\"nowrap\">",
"     familial/genetic",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     nonfamilial/non-genetic",
"    </span>",
"    causes of cardiomyopathy and excluding heart disease secondary to coronary artery disease, valvular, or congenital heart disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The five types of cardiomyopathy are as follows (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilated cardiomyopathy arising as primary myocardial disease of unknown etiology or as disorders of toxic, familial, or infective origin. In clinical practice, ischemic cardiomyopathy is frequently viewed as a type of dilated cardiomyopathy, although current major society classification systems exclude it [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link\">",
"       \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy including various causes of increased left ventricular wall thickness not caused by hypertension or valve disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"       \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .) Restrictive cardiomyopathy, including cardiac amyloidosis and endomyocardial fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"       \"Idiopathic restrictive cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"       \"Endomyocardial fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unclassified cardiomyopathy, including ventricular noncompaction (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"       \"Isolated left ventricular noncompaction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the echocardiographic features of the various types of cardiomyopathy. The general evaluation of the patient with heart failure or cardiomyopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DILATED CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of one or both ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/4\">",
"     4",
"    </a>",
"    ]. Dilated cardiomyopathy is readily identified by echocardiography when it is fully developed but is more difficult to detect in its early stages. Without the clinical history, patient examination, and other diagnostic test results, echocardiography alone is often unable to establish the cause of myocardial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Echocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most distinctive two-dimensional (2D) echocardiographic findings in a dilated cardiomyopathy are left ventricular spherical dilatation, normal or reduced wall thickness, poor systolic wall thickening,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced inward endocardial systolic motion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65679 \" href=\"UTD.htm?5/17/5407\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67315 \" href=\"UTD.htm?6/51/6961\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50731 \" href=\"UTD.htm?17/44/18115\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58760 \" href=\"UTD.htm?7/22/7522\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66421 \" href=\"UTD.htm?7/4/7237\">",
"     image 4",
"    </a>",
"    ). All of the systolic indices are reduced, including left ventricular fractional shortening, fractional area change, and ejection fraction (",
"    <a class=\"graphic graphic_movie graphicRef78668 \" href=\"UTD.htm?40/35/41521\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef75021 \" href=\"UTD.htm?43/0/44035\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68493 \" href=\"UTD.htm?38/61/39902\">",
"     movie 3",
"    </a>",
"    ). Four chamber cardiac enlargement is often present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67315 \" href=\"UTD.htm?6/51/6961\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50731 \" href=\"UTD.htm?17/44/18115\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66421 \" href=\"UTD.htm?7/4/7237\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    On M-mode echocardiography, additional features related to systolic dysfunction are increased separation of the mitral leaflet E point from the septum, poor mitral valve opening, poor aortic valve opening and early closure from a reduced stroke volume, and poor systolic aortic root motion (",
"    <a class=\"graphic graphic_figure graphicRef58760 \" href=\"UTD.htm?7/22/7522\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66421 \" href=\"UTD.htm?7/4/7237\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66756 \" href=\"UTD.htm?3/1/3091\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63276 \" href=\"UTD.htm?3/12/3270\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53355 \" href=\"UTD.htm?29/56/30592\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/5\">",
"     5",
"    </a>",
"    ]. A two-dimensional image of a normal heart in a young athlete with a slow heart rate may qualitatively suggest dilated cardiomyopathy. However, the M-mode will be normal and not display any of the above features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left ventricular volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the American Society of Echocardiography guidelines, quantitative measurements should be obtained for accurate evaluation of cardiac chamber sizes. While linear (M-mode) measurements are useful, they may not reflect true cardiac dimensions, especially in distorted ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients with dilated cardiomyopathy, the left ventricle end-diastolic volume index often exceeds 100",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (upper normal is approximately 75",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. The left ventricular ejection fraction, derived from the end-systolic volume (ESV) and end-diastolic volume (EDV) determinations can, at times, fall below 20 percent, but is usually between 20 and 40 percent (normal &ge;55 percent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72326 \" href=\"UTD.htm?18/34/18982\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68362 graphicRef70139 \" href=\"UTD.htm?17/5/17496\">",
"     figure 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite the reduced left ventricular ejection fraction, cardiac output calculations (stroke volume times heart rate) are frequently normal. There are two reasons for this finding. First, patients with cardiomyopathy frequently have elevated heart rates. Second, since the stroke volume is equal to the product of the left ventricular end-diastolic volume and ejection fraction, the effect of a low ejection fraction can be counterbalanced by an elevation in end-diastolic volume. As an example, a patient with an end-diastolic volume of 200 mL, an ejection fraction of 30 percent, and a heart rate of 100 beats per minute has a cardiac output of 6",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    In large hearts, accurate measurement of volume and their reproducibility are enhanced by using a microbubble contrast agent to improve detection of the boundary between the myocardium and blood pool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     End-systolic volume index",
"    </span>",
"    &nbsp;&mdash;&nbsp;We routinely measure the left ventricular end-systolic volume index (ESVI) because it provides important information in several clinical settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ESVI that rises progressively from normal (&lt;20",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      or that approaches or exceeds 30",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is an important clinical indicator of deteriorated global function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with ischemic cardiomyopathy who have global dysfunction with segmental evidence of infarction, an ESVI of 45",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      identifies patients with a poor outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the later Heart and Soul study, the risk of an adverse outcome began to increase sharply once the end systolic volume exceeded",
"      <span class=\"nowrap\">",
"       25mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Right ventricle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the right heart is important because it implies pulmonary hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricular failure secondary to either pulmonary pressure elevation or to primary involvement of the right ventricular myocardium in the pathologic process. The prognosis is considerably worsened when there is right ventricular dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduced right ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A useful and easily obtained measurement of right ventricular function is the tricuspid annular plane systolic excursion, also called TAPSE, an expression of longitudinal muscle function or descent of the right ventricular cardiac base. In one report, an excursion &le;14 mm added significant prognostic information to other clinical and echocardiographic findings in dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H7#H7\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Right ventricular function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gradients of tricuspid regurgitation and end diastolic pulmonary regurgitation correlate with pulmonary artery systolic and diastolic pressures, and have been shown to predict heart failure hospitalization and mortality in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Left atrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left atrial end-systolic volume index may be increased and often exceeds 50",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (upper limits of normal approximately 28",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. Left atrial volume estimates from biplane 2D measurements are more accurate than single linear dimensions for measuring left atrial size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler has been used in dilated cardiomyopathy to measure decreased stroke volume. The velocity time integral of the left ventricular outflow tract is decreased (&lt;18 cm) in this disorder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81391 \" href=\"UTD.htm?13/18/13601\">",
"     image 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, acceleration or deceleration of the mitral regurgitant jet can be used as an analog of",
"    <span class=\"nowrap\">",
"     dP/dT",
"    </span>",
"    (ie, the change in left ventricular pressure over time) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, one study of 61 patients found that",
"    <span class=\"nowrap\">",
"     dP/dT",
"    </span>",
"    &lt;600",
"    <span class=\"nowrap\">",
"     mmHg/sec",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     -dP/DT",
"    </span>",
"    &lt;450",
"    <span class=\"nowrap\">",
"     mmHg/sec",
"    </span>",
"    identified a high risk group with a reduced event-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitral regurgitation is a constant feature of dilated cardiomyopathy and is usually mild to moderate in severity but, on occasion, may be severe. The pathophysiology of mitral regurgitation in dilated cardiomyopathy is usually not due to organic leaflet disease but rather due to abnormal leaflet tethering mandated by the change in LV shape from ellipsoid to spherical. As cardiomyopathy progresses, the point of leaflet coaptation migrates from its normal basal location to a spot deeper in the LV cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of mitral inflow patterns can identify patients with restrictive physiology due to diastolic dysfunction (",
"    <a class=\"graphic graphic_waveform graphicRef59321 \" href=\"UTD.htm?5/31/5618\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .) Restrictive or pseudonormal diastolic inflow patterns connote a poor prognosis and aid in guiding treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Patients with dilated cardiomyopathy have abnormally low diastolic suction and blunted capacity to recruit suction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulmonary vein flow signal should always be sought as an adjunct to the mitral inflow pattern. Abnormal pulmonary venous systolic flow patterns have been shown to correlate with future development of pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/23\">",
"     23",
"    </a>",
"    ]. Loss of the systolic dominant flow pattern suggests elevated filling pressure. Pulmonary venous flow reversal duration minus mitral inflow duration at atrial contraction &gt;30 ms predicts mortality and hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, Doppler tissue imaging has patterns associated with elevated left ventricular filling pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H5#H5\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Concomitant diastolic dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac synchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic methods of evaluation for left ventricular dyssynchrony include: M-mode septal to posterior wall motion delay, pre-ejection right and left ventricular time intervals, Doppler tissue imaging delay, strain, strain rate, and tissue tracking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link&amp;anchor=H19#H19\">",
"     \"Cardiac resynchronization therapy in heart failure: Implantation and other considerations\", section on 'Other measures of dyssynchrony'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Features of specific types of dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although echocardiography cannot distinguish the specific cause of dilated cardiomyopathy, certain types of disease processes have characteristic echocardiographic features.",
"   </p>",
"   <p>",
"    Ischemic cardiomyopathy is a common cause of heart failure that can be difficult to differentiate from idiopathic dilated cardiomyopathy. In both ischemic and idiopathic forms, left ventricular wall motion abnormalities and the intensity of scarring can be segmentally variable or heterogeneous. In most patients, ischemic cardiomyopathy is associated with regional remodeling, which is characterized by local segments that have their own radius of curvature. Ischemic cardiomyopathy also tends to have areas of endocardial brightening or scarring that occurs in the areas where infarctions are most common: the inferior base, mid to distal septum, and the apex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ischemic cardiomyopathy tend to have calcification of the aortic annulus, aortic valve, sinotubular junction, mitral annulus, papillary muscle, and proximal coronaries. They may also have visible plaque in the aortic arch and abdominal aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of dilated cardiomyopathy\", section on 'Ischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypertensive cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypertensive cardiomyopathy tend to have greater left ventricular wall thickness and mass, dilated aortic root and ascending aorta, and calcification in the areas listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chagasic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occurring in South and Central American countries, the finding of a segmental cardiomyopathy raises the possibility of Chagas disease; more advanced disease produces the nonspecific finding of a generalized dilated cardiomyopathy. In its segmental form, Chagas disease typically presents with one or more areas of dyssynergy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The most common abnormality is an apical aneurysm which, unlike coronary disease, partly spares the interventricular septum. In a less common segmental presentation, the inferior base can be the site of segmentally isolated thinning and scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR HYPERTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy is characterized by increased left ventricular mass, which is quantitated by determining the wall thicknesses and estimating the left ventricular wall mass. When these findings are present without apparent etiology, the cause of hypertrophy in the majority of cases is mutation in a gene encoding cardiac sarcomeric proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left ventricular hypertrophy is considered secondary when due to an identifiable disorder such as hypertension or aortic stenosis. The hypertrophy is usually asymmetric in inherited hypertrophic cardiomyopathy, and symmetric in secondary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The predictive accuracy of the pattern of hypertrophy for genetically determined versus secondary HCM, however, is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiographic diagnosis of HCM is based upon the finding of an otherwise unexplained hypertrophied, nondilated left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/35\">",
"     35",
"    </a>",
"    ]. A septal wall thickness &ge; 15 mm has been commonly used to diagnose HCM, although other causes for hypertrophy must be excluded and some patients with HCM do not meet this threshold for septal thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/36\">",
"     36",
"    </a>",
"    ]. The degree and distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy are variable, and include septal hypertrophy with or without obstruction to left ventricular outflow, concentric hypertrophy, apical hypertrophy, hypertrophy of the left ventricular free wall, and right ventricular hypertrophy (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/9\">",
"     9",
"    </a>",
"    ]. One characteristic pattern is asymmetric septal hypertrophy (ASH) with wall thickness greatest at the basal septum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. ASH is recognized by a septal to posterior wall ratio of 1.5 to 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a more unusual and often more clinically benign variant of HCM, the apex is the site of the greatest hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Apical hypertrophy is more difficult to identify by echocardiography because the apical myocardium is more difficult to image (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51194 \" href=\"UTD.htm?19/43/20144\">",
"     image 10",
"    </a>",
"    ). When this condition is suspected (eg, by finding deeply inverted precordial T waves on ECG), it is helpful to use an echocardiographic contrast agent to confirm the diagnosis and identify the small apical aneurysm that may form distal to the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/40\">",
"     40",
"    </a>",
"    ]. Cardiac magnetic resonance imaging is a preferred imaging test for",
"    <span class=\"nowrap\">",
"     identification/exclusion",
"    </span>",
"    of the apical hypertrophic syndrome since it can detect apical aneurysms missed by echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link&amp;anchor=H5#H5\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Apical HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Echocardiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram with Doppler is the most practical means to assess the hemodynamics of HCM. Approximately 20 to 25 percent of patients have a resting left ventricular outflow tract gradient of greater than 30 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/41\">",
"     41",
"    </a>",
"    ]. However, when the obstruction is dynamic, ie, provocable but mild or absent at rest, the task of the echocardiographic laboratory is more difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of Doppler techniques, particularly continuous wave, is mandatory. This modality is typically used to measure the systolic flow velocity in the left ventricular outflow tract and mid cavity at rest and during maneuvers (eg, Valsalva; normal 0.9",
"    <span class=\"nowrap\">",
"     m/sec)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef67484 \" href=\"UTD.htm?7/24/7555\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Doppler in this setting will also enable the recognition of dynamic mitral regurgitation that often appears with a posteriorly directed jet in concert with outflow tract obstruction. Patients with left ventricular outflow tract obstruction often have the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymmetric septal hypertrophy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78895 \" href=\"UTD.htm?38/34/39471\">",
"       image 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70534 \" href=\"UTD.htm?39/17/40214\">",
"       image 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78856 \" href=\"UTD.htm?18/7/18559\">",
"       image 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systolic anterior motion of the mitral valve (SAM) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55693 \" href=\"UTD.htm?26/23/27006\">",
"       image 14",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50651 \" href=\"UTD.htm?17/54/18279\">",
"       image 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef79426 \" href=\"UTD.htm?0/20/321\">",
"       movie 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef65618 \" href=\"UTD.htm?29/63/30705\">",
"       movie 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Crowding of the mitral apparatus by the left ventricular outflow tract (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50651 \" href=\"UTD.htm?17/54/18279\">",
"       image 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef65618 \" href=\"UTD.htm?29/63/30705\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51424 \" href=\"UTD.htm?11/48/12032\">",
"       image 16",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Partial early systolic closure or notching of the aortic valve (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75078 \" href=\"UTD.htm?8/21/8532\">",
"       image 17",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Calcification of the mitral annulus frequently accompanies hypertrophic cardiomyopathy, and, in some patients, this finding is the only clue to the potential for dynamic outflow tract obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitral regurgitation often accompanies obstruction and the mitral regurgitation jet needs to be distinguished from the gradient jet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Provocative maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever obstructive or nonobstructive HCM is suspected but not overt, it is often desirable to perform some sort of intervention or provocation during the echocardiographic examination; the most frequently used maneuver is the Valsalva maneuver and the most common pharmacologic intervention is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    inhalation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51424 \" href=\"UTD.htm?11/48/12032\">",
"     image 16",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of Doppler techniques, particularly continuous wave, is mandatory. This modality is typically used to measure the systolic flow velocity in the left ventricular outflow tract and mid cavity at rest and during maneuvers (normal 0.9",
"      <span class=\"nowrap\">",
"       m/sec)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Doppler in this setting will also enable the recognition of dynamic mitral regurgitation that often appears in concert with outflow tract obstruction. Distinguishing mitral regurgitation from an outflow tract gradient can be challenging for the sonographer.",
"     </li>",
"     <li>",
"      Systolic anterior movement of the mitral valve (SAM) on two-dimensional and M-mode imaging provides independent evidence of dynamic obstruction, particularly if there is also contact of the mitral leaflet tip and the septum; the more severe the obstruction, the more prolonged the contact (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55693 \" href=\"UTD.htm?26/23/27006\">",
"       image 14",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50651 \" href=\"UTD.htm?17/54/18279\">",
"       image 15",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If obstruction worsens with provocation, SAM will also worsen. SAM is graded as follows:",
"   </p>",
"   <p>",
"    &nbsp;0 = absent",
"   </p>",
"   <p>",
"    &nbsp;1+ = present, with a minimum distance between the mitral valve and ventricular septum during systole &gt;10 mm",
"   </p>",
"   <p>",
"    &nbsp;2+ = without mitral-septal contact, but with a distance of &lt;10 mm between the mitral valve and septum",
"   </p>",
"   <p>",
"    &nbsp;3+ = brief mitral-septal contact (&lt;30 percent of echocardiographic systole)",
"   </p>",
"   <p>",
"    &nbsp;4+ = prolonged apposition of the mitral valve leaflet with the septum (&gt;30 percent of echocardiographic systole)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection of the aortic valve at the peak of provocation will provide secondary evidence of obstruction by demonstrating early systolic closure (producing a peak and dome configuration on M-mode echocardiography) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75078 \" href=\"UTD.htm?8/21/8532\">",
"       image 17",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Valsalva maneuver is usually performed first, and if it fails to provoke changes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    inhalation may sometimes be used. During this more vigorous provocation the same structures are monitored. It is ideal during any intervention to have someone performing auscultation. If technical problems interfere with echocardiography or Doppler, detection of a new or worsening murmur, particularly if intense, may be sufficient to identify a culprit condition. Exercise testing may also be used to evaluate this condition. We use supine bicycle so that it is possible to image the heart and sample flow by Doppler during and after the stress test. In this way changes in gradient, severity of mitral regurgitation, and rhythm may be sought. Note that the dynamic outflow gradient often does not worsen until the immediate post-exercise period. This behavior of dynamic obstruction often mimics a common symptom complex in HCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other causes of left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of left ventricular hypertrophy include hypertension, aortic stenosis, and so-called athlete's heart. The differential diagnosis of left ventricular hypertrophy is discussed separately. Secondary left ventricular hypertrophy is most commonly encountered as a complication of hypertension. The presence of left ventricular hypertrophy in a hypertensive subjects increases the likelihood of cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H2599189#H2599189\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Differential diagnosis of LVH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Echocardiographic features of secondary left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the procedure of choice for identifying secondary left ventricular hypertrophy since the sensitivity of the various electrocardiographic (ECG) criteria may be as low as 7 to 35 percent with mild left ventricular hypertrophy and only 10 to 50 percent with moderate to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, echocardiographic criteria for the diagnosis of left ventricular hypertrophy were largely based on M-mode echocardiography and included a left ventricular mass index &ge;134 and &ge;110",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area in men and women, respectively (",
"    <a class=\"graphic graphic_figure graphicRef63653 \" href=\"UTD.htm?6/38/6757\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58732 graphicRef61196 \" href=\"UTD.htm?37/4/37959\">",
"     image 18A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61383 \" href=\"UTD.htm?29/12/29889\">",
"     image 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60104 \" href=\"UTD.htm?0/56/899\">",
"     image 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef76903 \" href=\"UTD.htm?33/47/34547\">",
"     waveform 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the echocardiographic studies of left ventricular hypertrophy have relied on M-mode echocardiography (",
"    <a class=\"graphic graphic_waveform graphicRef76903 \" href=\"UTD.htm?33/47/34547\">",
"     waveform 3",
"    </a>",
"    ). However, M-mode echocardiography may not be ideally suited for this task because of a relatively low yield in older patients, suboptimal reproducibility, possible erroneous results in distorted ventricles, and use of a geometric algorithm that tends to overestimate mass. Two-dimensional echocardiography increase the precision and produce estimates of left ventricular mass that more closely approximate values derived from pathology, magnetic resonance imaging, and computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used 2D methods for measure of left ventricular mass are area-length and truncated ellipse. Both methods have been previously validated and endorsed by the American Society of Echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/51\">",
"     51",
"    </a>",
"    ]. The most recent American Society of Echocardiography published guidelines for diagnosis of left ventricular hypertrophy included criteria for mild, moderate, and severe left ventricular hypertrophy for men as 103 to 116, 117 to 130, &gt;130",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and for women as 89 to 100, 101 to 112, &gt;112",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. We consider left ventricular mass index &gt;95",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    indicative of abnormally increased left ventricular mass based on outcome data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Sigmoid septum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal apparent hypertrophy of the basal interventricular septum (known as sigmoid septum) occurs commonly in older adults, seemingly as the result of an age-related shift in the orientation of the LV long axis from vertical to horizontal. Contrast imaging of the left ventricle suggests that there is little, if any, hypertrophy. Importantly, the axis shift of these hearts elongates the short axis view and can exaggerate calculated LV mass (by truncated ellipse or area length methods) to a degree that results in overestimation of the degree of hypertrophy. As a rule, if wall motion is not thickened and LV volume normal, an elevated mass in sigmoid septum is likely artifactual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RESTRICTIVE CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive cardiomyopathy is characterized by a nondilated (or small,",
"    <span class=\"nowrap\">",
"     &lt;40mL/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    left ventricle with impaired ventricular filling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/54\">",
"     54",
"    </a>",
"    ]. Hypertrophy is typically absent, although infiltrative disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an increase in left ventricular wall thickness. Systolic function usually remains normal, at least early in the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H8#H8\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Restrictive cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathies are more difficult to diagnose with echocardiography than dilated or hypertrophic cardiomyopathies, and may be challenging to distinguish from constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography, including Doppler interrogation, is the most effective noninvasive means for the recognition of this group of conditions. Restrictive cardiomyopathy is characterized by a low or normal diastolic volume, normal or only mildly reduced left ventricular ejection fraction, atrial enlargement, normal pericardium, and abnormal diastolic function. Diastolic dysfunction is frequently restrictive, with an elevated peak mitral inflow velocity, rapid early mitral inflow deceleration, and reduced Doppler tissue imaging early annular velocity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most common restrictive cardiomyopathy is the small, stiff heart of diabetes in which diastolic dysfunction is the predominant functional abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/55\">",
"     55",
"    </a>",
"    ]. In the majority of diabetics, this condition is clinically unapparent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Quantitation of left ventricular function reveals a normal ejection fraction and left ventricular volumes that are lower than expected. This condition is suspected as a predisposing factor when, for example, diabetics with critical coronary artery stenosis and normal left ventricular systolic function develop pulmonary congestion in association with angina or acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link\">",
"     \"Heart failure in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Amyloid infiltrative cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid heart disease is an uncommon disorder that can occur as part as systemic primary (AL) or secondary (AA) amyloidosis or as an isolated cardiac condition in patients with senile amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The last condition is more common in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], apparently due to a higher frequency of a predisposing variant in the transthyretin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/60\">",
"     60",
"    </a>",
"    ]. When the amyloid precursor protein is produced by the liver, liver transplantation may halt the process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .) The prognosis is poor, especially in those who exhibit restrictive diastolic filling patterns by Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diastolic dysfunction is the most common, earliest, and most important echocardiographic abnormality in cardiac amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography in patients with overt cardiac amyloidosis frequently demonstrates symmetric left ventricular wall thickening, typically involving the interventricular septum, small ventricular chambers, thickening of the atrial septum, pericardial effusion, and dilated atria (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78406 \" href=\"UTD.htm?24/46/25312\">",
"     image 21",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59273 \" href=\"UTD.htm?23/63/24575\">",
"     image 22",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61904 \" href=\"UTD.htm?36/40/37507\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64330 \" href=\"UTD.htm?43/47/44787\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78037 \" href=\"UTD.htm?41/31/42481\">",
"     movie 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Increased right ventricular wall thickness, when present, may be associated with right ventricular diastolic dysfunction, which can be demonstrated by Doppler examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/63\">",
"     63",
"    </a>",
"    ]. Disproportionate right ventricular enlargement may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another common echocardiographic finding in cardiac amyloidosis is a granular, \"sparkling\" appearance of the myocardium, resulting from the presence of amyloid and collagen nodules in the heart (",
"    <a class=\"graphic graphic_movie graphicRef61904 \" href=\"UTD.htm?36/40/37507\">",
"     movie 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/62,65-67\">",
"     62,65-67",
"    </a>",
"    ]. This finding alone is relatively nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/68\">",
"     68",
"    </a>",
"    ] but the combination of these refractile echoes, atrial septum thickening, and low ECG voltage are highly suggestive of cardiac amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apparent preservation or exaggeration of contractile function in a subgroup of patients with amyloid cardiomyopathy is explained by very low wall stress, which is the ultimate expression of afterload and is greatly reduced by the combination of thickened walls, very small cavity, and low generated systolic pressure (arterial hypotension). When contractile function is preserved, amyloid cardiomyopathy can be mistaken for hypertrophic cardiomyopathy and diagnosis can be delayed. A patient with low blood pressure, low ECG voltage, a pacemaker, and the above features should immediately arouse suspicion of the advanced stage of this form of lethal infiltrative cardiomyopathy. Early disease may be difficult to differentiate from other forms of cardiac disease and may only be manifest upon serial echocardiograms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Endomyocardial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial fibrosis is a cause of restrictive cardiomyopathy in North Africa and South America. The condition is associated with eosinophilia in about 50 percent of those afflicted, and is also known as Loeffler's or Davies disease when encountered in North Africa.",
"   </p>",
"   <p>",
"    The recognition of endomyocardial fibrosis depends on a high level of clinical suspicion and characteristic echocardiographic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/30,69\">",
"     30,69",
"    </a>",
"    ]. There are mass-like apical lesions in the left ventricle resulting from a thrombotic fibrocalcific process. These lesions are associated with restriction of left ventricular and right ventricular filling due to obliteration of one or both cardiac apices (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77099 \" href=\"UTD.htm?30/19/31024\">",
"     image 23",
"    </a>",
"    ). In addition to the unique appearance of the apices, the atria are strikingly enlarged and mitral and tricuspid regurgitation are often present. As the condition progresses, more and more of the left ventricular cavity is obliterated, leading to a progressively restrictive physiology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65132 \" href=\"UTD.htm?8/42/8866\">",
"     image 24",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"     \"Endomyocardial fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC) or dysplasia (ARVD) or is a category of cardiomyopathy characterized by fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apex of the right ventricle. In its most severe form it is called Uhl's disease or parchment right ventricle. ARVC is difficult to diagnose by echocardiography due to limited sensitivity and specificity of echocardiographic features. The 2010 revised Task Force major echocardiographic criterion was developed to yield 95 percent specificity and requires regional right ventricular",
"    <span class=\"nowrap\">",
"     akinesis/dyskinesis",
"    </span>",
"    or aneurysm plus either right ventricular outflow dilatation or reduced fractional area change (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"     6",
"    </a>",
"    ]. Minor echocardiographic criteria were selected to yield sensitivity equal to specificity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study using 3-D echocardiography with Doppler tissue imaging demonstrated that patients with ARVC had lower right ventricular ejection fraction, decreased lateral right ventricular and left ventricular systolic annular velocity, and decreased regional systolic strain compared to age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/12/15562/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR NONCOMPACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular noncompaction, also called left ventricular hypertrabeculation or spongy myocardium, is an uncommon cause of cardiomyopathy that results from intrauterine arrest of compaction of the loose interwoven meshwork that makes up the fetal myocardial primordium. This disorder should be suspected when unexpectedly heavy left ventricular trabeculation is noted, particularly toward the lateral apex. Cardiac magnetic resonance imaging is often a preferred imaging method for this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noncompaction has been reassigned to the \"unclassified\" category of cardiomyopathy, which also includes stress (takotsubo) cardiomyopathy (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Unclassified cardiomyopathies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979715\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography is the primary diagnostic modality for identification and differentiation of the various types of cardiomyopathy (",
"      <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15920411\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The five types of cardiomyopathy are dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H15920411\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H1978197#H1978197\">",
"       \"Definition and classification of the cardiomyopathies\", section on 'Major Society Criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most distinctive two-dimensional echocardiographic findings in a dilated cardiomyopathy are left ventricular spherical dilatation, normal or reduced wall thickness, poor systolic wall thickening,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduced inward endocardial systolic motion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65679 \" href=\"UTD.htm?5/17/5407\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67315 \" href=\"UTD.htm?6/51/6961\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50731 \" href=\"UTD.htm?17/44/18115\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58760 \" href=\"UTD.htm?7/22/7522\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66421 \" href=\"UTD.htm?7/4/7237\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Echocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The echocardiographic diagnosis of hypertrophic cardiomyopathy (HCM) is based upon the finding of an otherwise unexplained hypertrophied, nondilated left ventricle. A septal thickness &ge; 15 mm has been commonly used to diagnose HCM, although other causes for hypertrophy must be excluded and some patients with HCM do not meet this threshold for septal thickness. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hypertrophic cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restrictive cardiomyopathy is characterized by nondilated ventricles with impaired ventricular filling. Hypertrophy is typically absent, although infiltrative disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an increase in left ventricular wall thickness. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Restrictive cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H8#H8\">",
"       \"Definition and classification of the cardiomyopathies\", section on 'Restrictive cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a category of cardiomyopathy characterized by fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow tract,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      apex of the right ventricle. Echocardiographic diagnosis of ARVC is difficult due to limited sensitivity and specificity. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Arrhythmogenic right ventricular cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The &ldquo;unclassified&rdquo; cardiomyopathies include left ventricular noncompaction and stress cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H11#H11\">",
"       \"Definition and classification of the cardiomyopathies\", section on 'Unclassified cardiomyopathies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"       \"Isolated left ventricular noncompaction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/1\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/2\">",
"      Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/3\">",
"      Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/4\">",
"      Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/5\">",
"      Gardin JM, Tommaso CL, Talano JV. Echographic early systolic partial closure (notching) of the aortic valve in congestive cardiomyopathy. Am Heart J 1984; 107:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/6\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/7\">",
"      McManus DD, Shah SJ, Fabi MR, et al. Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. J Am Soc Echocardiogr 2009; 22:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/8\">",
"      White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/9\">",
"      Sun JP, James KB, Yang XS, et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities. Am J Cardiol 1997; 80:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/10\">",
"      de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/11\">",
"      Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000; 85:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/12\">",
"      Ristow B, Ali S, Ren X, et al. Elevated pulmonary artery pressure by Doppler echocardiography predicts hospitalization for heart failure and mortality in ambulatory stable coronary artery disease: the Heart and Soul Study. J Am Coll Cardiol 2007; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/13\">",
"      Maddukuri PV, Vieira ML, DeCastro S, et al. What is the best approach for the assessment of left atrial size? Comparison of various unidimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume. J Am Soc Echocardiogr 2006; 19:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/14\">",
"      Ristow B, Na B, Ali S, et al. Left ventricular outflow tract and pulmonary artery stroke distances independently predict heart failure hospitalization and mortality: the Heart and Soul Study. J Am Soc Echocardiogr 2011; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/15\">",
"      Loutfi H, Nishimura RA. Quantitative evaluation of left ventricular systolic function by Doppler echocardiographic techniques. Echocardiography 1994; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/16\">",
"      Kolias TJ, Aaronson KD, Armstrong WF. Doppler-derived dP/dt and -dP/dt predict survival in congestive heart failure. J Am Coll Cardiol 2000; 36:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/17\">",
"      Pozzoli M, Traversi E, Cioffi G, et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997; 95:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/18\">",
"      Rihal CS, Nishimura RA, Hatle LK, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 1994; 90:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/19\">",
"      Temporelli PL, Corr&agrave; U, Imparato A, et al. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998; 31:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/20\">",
"      Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22:808.",
"     </a>",
"    </li>",
"    <li>",
"     Ren, X, Ristow, B, Na, B, et al. Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol (in press).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/22\">",
"      Yotti R, Bermejo J, Antoranz JC, et al. A noninvasive method for assessing impaired diastolic suction in patients with dilated cardiomyopathy. Circulation 2005; 112:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/23\">",
"      Dini FL, Nuti R, Barsotti L, et al. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography 2002; 19:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/24\">",
"      Dini FL, Michelassi C, Micheli G, Rovai D. Prognostic value of pulmonary venous flow Doppler signal in left ventricular dysfunction: contribution of the difference in duration of pulmonary venous and mitral flow at atrial contraction. J Am Coll Cardiol 2000; 36:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/25\">",
"      Zamorano J, P&eacute;rez de Isla L, Roque C, Khanhderia B. The role of echocardiography in the assessment of mechanical dyssynchrony and its importance in predicting response to prognosis after cardiac resynchronization therapy. J Am Soc Echocardiogr 2007; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     Agler, DA. Cardiac resynchronization therapy and the emerging role of echocardiography (part 2): the comprehensive examination.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/27\">",
"      Waggoner AD, Agler DA, Adams DB. Cardiac resynchronization therapy and the emerging role of echocardiography (part 1): indications and results from current studies. J Am Soc Echocardiogr 2007; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/28\">",
"      Bleeker GB, Schalij MJ, Boersma E, et al. Relative merits of M-mode echocardiography and tissue Doppler imaging for prediction of response to cardiac resynchronization therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2007; 99:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/29\">",
"      Acquatella H, Schiller NB, Puigb&oacute; JJ, et al. M-mode and two-dimensional echocardiography in chronic Chages' heart disease. A clinical and pathologic study. Circulation 1980; 62:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/30\">",
"      Acquatella H, Schiller NB. Echocardiographic recognition of Chagas' disease and endomyocardial fibrosis. J Am Soc Echocardiogr 1988; 1:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/31\">",
"      Maron BJ, Nichols PF 3rd, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984; 53:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/32\">",
"      Cir&oacute; E, Nichols PF 3rd, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Circulation 1983; 67:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/33\">",
"      Maron BJ. Asymmetry in hypertrophic cardiomyopathy: the septal to free wall thickness ratio revisited. Am J Cardiol 1985; 55:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/34\">",
"      Nair CK, Kudesia V, Hansen D, et al. Echocardiographic and electrocardiographic characteristics of patients with hypertrophic cardiomyopathy with and without mitral anular calcium. Am J Cardiol 1987; 59:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/35\">",
"      Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/36\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/37\">",
"      Kereiakes DJ, Anderson DJ, Crouse L, Chatterjee K. Apical hypertrophic cardiomyopathy. Am Heart J 1983; 105:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/38\">",
"      Maron BJ, Bonow RO, Seshagiri TN, et al. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). Am J Cardiol 1982; 49:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/39\">",
"      Vacek JL, Davis WR, Bellinger RL, McKiernan TL. Apical hypertrophic cardiomyopathy in American patients. Am Heart J 1984; 108:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/40\">",
"      Otieno H, Vivas Y, Traub D, et al. Images in cardiovascular medicine: contrast echocardiography in apical hypertrophic cardiomyopathy. Circulation 2006; 114:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/41\">",
"      Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/42\">",
"      Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/43\">",
"      Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/44\">",
"      Pollick C, Morgan CD, Gilbert BW, et al. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982; 66:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/45\">",
"      Leenen FH. Increased risk attributed to left ventricular hypertrophy in hypertension. Curr Opin Cardiol 1996; 11:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/46\">",
"      Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation 1990; 81:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/47\">",
"      Abergel E, Tase M, Bohlender J, et al. Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol 1995; 75:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/48\">",
"      Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/49\">",
"      Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997; 15:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/50\">",
"      Gopal AS, Schnellbaecher MJ, Shen Z, et al. Freehand three-dimensional echocardiography for measurement of left ventricular mass: in vivo anatomic validation using explanted human hearts. J Am Coll Cardiol 1997; 30:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/51\">",
"      Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/52\">",
"      Stevens SM, Farzaneh-Far R, Na B, et al. Development of an echocardiographic risk-stratification index to predict heart failure in patients with stable coronary artery disease: the Heart and Soul study. JACC Cardiovasc Imaging 2009; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/53\">",
"      Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol 2008; 102:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/54\">",
"      Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/55\">",
"      Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006; 48:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/56\">",
"      Bouchard A, Sanz N, Botvinick EH, et al. Noninvasive assessment of cardiomyopathy in normotensive diabetic patients between 20 and 50 years old. Am J Med 1989; 87:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/57\">",
"      P&eacute;rez JE, McGill JB, Santiago JV, et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992; 19:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/58\">",
"      Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983; 52:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/59\">",
"      Buck FS, Koss MN, Sherrod AE, et al. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol 1989; 2:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/60\">",
"      Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/61\">",
"      Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991; 83:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/62\">",
"      Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/63\">",
"      Klein AL, Hatle LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/64\">",
"      Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/65\">",
"      Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/66\">",
"      Nicolosi GL, Pavan D, Lestuzzi C, et al. Prospective identification of patients with amyloid heart disease by two-dimensional echocardiography. Circulation 1984; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/67\">",
"      Eriksson P, Eriksson A, Backman C, et al. Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy. A correlative echocardiographic and histopathological study. Acta Med Scand 1985; 217:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/68\">",
"      Bhandari AK, Nanda NC. Myocardial texture characterization by two-dimensional echocardiography. Am J Cardiol 1983; 51:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/69\">",
"      Acquatella H, Schiller NB, Puigb&oacute; JJ, et al. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/12/15562/abstract/70\">",
"      Kjaergaard J, Hastrup Svendsen J, Sogaard P, et al. Advanced quantitative echocardiography in arrhythmogenic right ventricular cardiomyopathy. J Am Soc Echocardiogr 2007; 20:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5330 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15562=[""].join("\n");
var outline_f15_12_15562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1979715\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15920411\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DILATED CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Echocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left ventricular volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      End-systolic volume index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Right ventricle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Left atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac synchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Features of specific types of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypertensive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chagasic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LEFT VENTRICULAR HYPERTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Echocardiographic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Provocative maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other causes of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Echocardiographic features of secondary left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Sigmoid septum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RESTRICTIVE CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Amyloid infiltrative cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LEFT VENTRICULAR NONCOMPACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1979715\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5330|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/17/5407\" title=\"diagnostic image 1\">",
"      Long axis view dilated CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/51/6961\" title=\"diagnostic image 2\">",
"      LV normal cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/44/18115\" title=\"diagnostic image 3\">",
"      2 D echo dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/4/7237\" title=\"diagnostic image 4\">",
"      M mode cardiomyopathy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/1/3091\" title=\"diagnostic image 5\">",
"      E point septal separation LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/12/3270\" title=\"diagnostic image 6\">",
"      M mode aorta dilated CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/56/30592\" title=\"diagnostic image 7\">",
"      M mode aorta cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/34/18982\" title=\"diagnostic image 8\">",
"      Estimation of LV volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/18/13601\" title=\"diagnostic image 9\">",
"      Pulsed wave Doppler LV outflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/43/20144\" title=\"diagnostic image 10\">",
"      Trabeculations HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/34/39471\" title=\"diagnostic image 11\">",
"      Long axis hypertrophic CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/17/40214\" title=\"diagnostic image 12\">",
"      M mode obstructive HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/7/18559\" title=\"diagnostic image 13\">",
"      Subcostal view HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/23/27006\" title=\"diagnostic image 14\">",
"      Long axis HCM ASH SAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/54/18279\" title=\"diagnostic image 15\">",
"      M mode hypertrophic CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/48/12032\" title=\"diagnostic image 16\">",
"      Provocable obstruction HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/21/8532\" title=\"diagnostic image 17\">",
"      M mode aorta hypertrophic CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/50/2848\" title=\"diagnostic image 18A\">",
"      Computer calculation of LV mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/54/10085\" title=\"diagnostic image 18B\">",
"      Short axis LV mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/12/29889\" title=\"diagnostic image 19\">",
"      LVH M mode echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/56/899\" title=\"diagnostic image 20\">",
"      4 chamber view LV mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/46/25312\" title=\"diagnostic image 21\">",
"      M mode amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/63/24575\" title=\"diagnostic image 22\">",
"      Apical 4 chamber amylodosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/19/31024\" title=\"diagnostic image 23\">",
"      LV endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/42/8866\" title=\"diagnostic image 24\">",
"      RV endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5330|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/22/7522\" title=\"figure 1\">",
"      M mode cardiomyopathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/36/6722\" title=\"figure 2A\">",
"      Sites LV measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19060\" title=\"figure 2B\">",
"      Algorithms LV volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 3\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/24/7555\" title=\"figure 4\">",
"      Pulsed Doppler HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/38/6757\" title=\"figure 5\">",
"      Estimation of LV mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5330|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/35/41521\" title=\"movie 1\">",
"      Dilated cardiomyopathy four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/0/44035\" title=\"movie 2\">",
"      Dilated cardiomyopathy long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/61/39902\" title=\"movie 3\">",
"      Dilated cardiomyopathy short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/20/321\" title=\"movie 4\">",
"      Apical 3 chamber echo HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/63/30705\" title=\"movie 5\">",
"      Long axis echo HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/40/37507\" title=\"movie 6\">",
"      Cardiac amyloidosis four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/47/44787\" title=\"movie 7\">",
"      Cardiac amyloidosis parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/31/42481\" title=\"movie 8\">",
"      Cardiac amyloidosis short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/63/18429\" title=\"table 1\">",
"      ESC 2008 CM familial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/42/8876\" title=\"table 2\">",
"      ESC 2008 CM nonfamilial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5330|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/31/5618\" title=\"waveform 1\">",
"      Doppler transmitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/45/32470\" title=\"waveform 2\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/47/34547\" title=\"waveform 3\">",
"      M mode echocardiography LV hypertrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=related_link\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_12_15563="Post therapy histology prostate";
var content_f15_12_15563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Posttherapy histologic features of the prostate gland",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Changes in prostate cancer cells",
"       </td>",
"       <td class=\"subtitle1\">",
"        Changes in benign epithelium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androgen ablation",
"       </td>",
"       <td>",
"        <p>",
"         Severe atrophic changes",
"        </p>",
"        <p>",
"         Clear or vacuolated cytoplasm",
"        </p>",
"        <p>",
"         Decreased nuclear atypia (Retained infiltrating pattern)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Severe atrophy",
"        </p>",
"        <p>",
"         Basal cell hyperplasia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen",
"       </td>",
"       <td>",
"        <p>",
"         Atrophic changes",
"        </p>",
"        <p>",
"         Squamous metaplasia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Squamous metaplasia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finasteride and dutasteride",
"       </td>",
"       <td>",
"        Minimal changes",
"       </td>",
"       <td>",
"        Mild atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation therapy",
"       </td>",
"       <td>",
"        Degenerative changes (Retained infiltrating pattern)",
"       </td>",
"       <td>",
"        Marked nuclear atypia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15563=[""].join("\n");
var outline_f15_12_15563=null;
var title_f15_12_15564="Urodynamic patterns";
var content_f15_12_15564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urodynamic patterns in normal and abnormal bladder conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Filling phase",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Voiding phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Detrusor contractions",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sphincter activity",
"       </td>",
"       <td class=\"subtitle2\">",
"        Detrusor contractions",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sphincter activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Normal",
"        </strong>",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        <strong>",
"         Abnormalities identified on urodynamic testing",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Overactive bladder",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Present",
"        </em>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Detrusor sphincter dyssynergy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Absent",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Present",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-neurogenic dysfunctional voiding",
"       </td>",
"       <td class=\"sublist_other\">",
"        Absent",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Present",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Underactive bladder",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Absent, large capacity bladder",
"        </em>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Present",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Inadequate, incomplete emptying",
"        </em>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Absent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15564=[""].join("\n");
var outline_f15_12_15564=null;
var title_f15_12_15565="Immune functions of cytokines";
var content_f15_12_15565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contributions of important cytokines to immunologic responses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Critical functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Cytokine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-1",
"       </td>",
"       <td>",
"        Macrophage",
"        <br/>",
"        Many cells",
"       </td>",
"       <td>",
"        Fever, induces other cytokines, T cell stimulation",
"        <br/>",
"        Induces metalloproteinases and prostglandins",
"        <br/>",
"        Increases adhesion molecule expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-2",
"       </td>",
"       <td>",
"        T cells",
"       </td>",
"       <td>",
"        Increase T cell proliferation, activates B cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-4",
"       </td>",
"       <td>",
"        T cells",
"       </td>",
"       <td>",
"        Signal for immunoglobulin switch, increases IgE",
"        <br/>",
"        Decreases production of proinflammatory cytokines",
"        <br/>",
"        Suppresses delayed type hypersensitivity (Th1 cells)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-6",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        B and T cell proliferation, acute phase reactants",
"        <br/>",
"        Induces natural protease inhibitor (TIMP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-12",
"       </td>",
"       <td>",
"        Macrophages",
"       </td>",
"       <td>",
"        Increase interferon-gamma production and Th1 cell differentiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-13",
"       </td>",
"       <td>",
"        T cells",
"       </td>",
"       <td>",
"        Similar to IL-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IL-15",
"       </td>",
"       <td>",
"        T cells",
"        <br/>",
"        Macrophages",
"       </td>",
"       <td>",
"        Induces TNF-alpha release from synovial macrophages, induces mitogenesis, and inhibits apoptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TNF-alpha",
"       </td>",
"       <td>",
"        T cells",
"        <br/>",
"        Macrophages",
"       </td>",
"       <td>",
"        Cachexia, induces other cytokines, T cell stimulation",
"        <br/>",
"        Induces metalloproteinases and prostaglandins",
"        <br/>",
"        Increases adhesion molecule expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IFN-gamma",
"       </td>",
"       <td>",
"        T cells",
"       </td>",
"       <td>",
"        Adhesion molecules, HLA-DR expression, activation of T cells, NK cells, macrophages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Colony stimulating factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GM-CSF",
"       </td>",
"       <td>",
"        Macrophages",
"        <br/>",
"        Fibroblasts",
"        <br/>",
"        T cells",
"       </td>",
"       <td>",
"        Myeloid differentiation, macrophage activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        G-CSF",
"       </td>",
"       <td>",
"        Macrophages",
"       </td>",
"       <td>",
"        Granulocyte differentiation and activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        M-CSF",
"       </td>",
"       <td>",
"        Macrophages",
"       </td>",
"       <td>",
"        Myeloid differentiation, macrophage activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Chemokines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C-X-C family",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        Activate neutrophils, chemotactic to neutrophil (IL-8, ENA- 78, etc) and T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C-C family",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        Chemotactic for monocytes and T cells (MCP-1, MIP-1, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Growth factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TGF-beta",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        Fibroblast proliferation, collagen and TIMP synthesis",
"        <br/>",
"        Decrease metalloproteinases, decreases T cell proliferation",
"        <br/>",
"        Angiogenesis, decreased pro-inflammatory cytokines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FGF, VEGF",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        Fibroblast proliferation, angiogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PDGF",
"       </td>",
"       <td>",
"        Many cells",
"       </td>",
"       <td>",
"        Fibroblast proliferation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15565=[""].join("\n");
var outline_f15_12_15565=null;
var title_f15_12_15566="Series rectal foreign bod";
var content_f15_12_15566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rectal foreign bodies series",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author (year)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Male/female",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age (mean or median in years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Insertion (anal/ingestion)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extraction (transanal/abdominal)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stoma (number)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Morbidity/mortality (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Volpi (2012)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;10",
"       </td>",
"       <td>",
"        &nbsp;7/3",
"       </td>",
"       <td>",
"        &nbsp;40",
"       </td>",
"       <td>",
"        &nbsp;10/0",
"       </td>",
"       <td>",
"        &nbsp;8/2",
"       </td>",
"       <td>",
"        &nbsp;1",
"       </td>",
"       <td>",
"        &nbsp;0/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rodriguez (2007)",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        20/10",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"       <td>",
"        16/14",
"       </td>",
"       <td>",
"        23/7",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        14/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarke (2005)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13/0",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        13/0",
"       </td>",
"       <td>",
"        8/5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lake (2004)",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        85/5",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        87/0",
"       </td>",
"       <td>",
"        79/8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruiz (2001)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        14/3",
"       </td>",
"       <td>",
"        46.3",
"       </td>",
"       <td>",
"        17/0",
"       </td>",
"       <td>",
"        10/7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biriukov (2000)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        111/1",
"       </td>",
"       <td>",
"        16-80",
"       </td>",
"       <td>",
"        112/0",
"       </td>",
"       <td>",
"        107/6",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ooi (1998)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        25/5",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        30/0",
"       </td>",
"       <td>",
"        27/3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        7/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cohen (1996)",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        45/3",
"       </td>",
"       <td>",
"        33.6",
"       </td>",
"       <td>",
"        48/0",
"       </td>",
"       <td>",
"        42/6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yaman (1993)",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        28/1",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"       <td>",
"        22/7",
"       </td>",
"       <td>",
"        27/2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        17/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marti (1986)",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        0/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nehme Kingsley (1985)",
"        <sup>",
"         [11]",
"        </sup>",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        51/0",
"       </td>",
"       <td>",
"        19-94",
"       </td>",
"       <td>",
"        51/0",
"       </td>",
"       <td>",
"        50/1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barone (1983)",
"        <sup>",
"         [12]",
"        </sup>",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        101/0",
"       </td>",
"       <td>",
"        16-48",
"       </td>",
"       <td>",
"        101/0",
"       </td>",
"       <td>",
"        89/12",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        NA/1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crass (1981)",
"        <sup>",
"         [13]",
"        </sup>",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        26/3",
"       </td>",
"       <td>",
"        10-84",
"       </td>",
"       <td>",
"        29/0",
"       </td>",
"       <td>",
"        15/14",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        14/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sohn (1977)",
"        <sup>",
"         [14]",
"        </sup>",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        11/0",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        11/0",
"       </td>",
"       <td>",
"        7/4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barone (1976)",
"        <sup>",
"         [15]",
"        </sup>",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        26/2",
"       </td>",
"       <td>",
"        16-56",
"       </td>",
"       <td>",
"        28/0",
"       </td>",
"       <td>",
"        23/5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not available.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Volpi A, Panebianco A, Ialongo P, et al. Colorectal retained&nbsp;foreign bodies&nbsp;per annum introduced. Three years retrospective study at Emergency Surgery Unit. &nbsp;G Chir&nbsp;2012; 33:411.",
"      <br>",
"       2. &nbsp;Rodriguez-Hermosa, JI, Codina-Cazador, A, Ruiz, B, et al. Management of foreign bodies in the rectum. Colorectal Dis 2007; 9:543.",
"       <br>",
"        3. &nbsp;Clarke, DL, Buccimazza, I, Anderson, FA, Thomson, SR. Colorectal foreign bodies. Colorectal Dis 2005; 7:98.",
"        <br>",
"         4. &nbsp;Lake, JP, Essani, R, Petrone, P, et al. Management of retained colorectal foreign bodies: predictors of operative intervention. Dis Colon Rectum 2004; 47:1694.",
"         <br>",
"          5. &nbsp;Ruiz de Castillo, J, Selles Dechent, R, Millan Scheiding, M, et al. Colorectal trauma caused by foreign bodies introduced during sexual activity: diagnosis and management. Rev Esp Enferm Dig 2001; 93:631.",
"          <br>",
"           6. &nbsp;Biriukov, IuV, Volkov, OV, An, VK, et al. Treatment of patients with foreign bodies in rectum. Khirugiia (Mosk) 2000; (7):41.",
"           <br>",
"            7. &nbsp;Ooi, BS, Ho, YH, Eu, KW, et al. Management of anorectal foreign bodies: a cause of obscure anal pain. Aust N Z J Surg 1998; 68:852.",
"            <br>",
"             8. &nbsp;Cohen, JS, Sackier, JM. Management of colorectal foreign bodies. J R Coll Surg Edinb 1996; 41:312.",
"             <br>",
"              9. &nbsp;Yaman, M, Deitel, M, Burul, CJ, et al. Foreign bodies in the rectum. Can J Surg 1993; 36:173.",
"              <br>",
"               10. &nbsp;Marti, MC, Morel, P, Rohner, A. Traumatic lesions of the rectum. Int J Colorectal Dis 1986; 1:152.",
"               <br>",
"                11. Nehme Kingsley, A, Abcarian, H. Colorectal foreign bodies. Management update. Dis Colon Rectum 1985; 28:941.",
"                <br>",
"                 12. Barone, JE, Yee, J, Nealon, TF Jr. Management of foreign bodies and trauma of the rectum. Surg Gynecol Obstet 1983; 156:453.",
"                 <br>",
"                  13. Crass, RA, Tranbaugh, RF, Kudsk, KA, Trunkey, DD. Colorectal foreign bodies and perforation. Am J Surg 1981; 142:85.",
"                  <br>",
"                   14. Sohn, N, Weinstein, MA, Gonchar, J. Social injuries of the rectum. Am J Surg 1977; 134:611.",
"                   <br>",
"                    15. Barone, JE, Sohn, N, Nealon, TF Jr. Perforations and foreign bodies of the rectum: report of 28 cases. Ann Surg 1976; 184:601.",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_12_15566=[""].join("\n");
var outline_f15_12_15566=null;
var title_f15_12_15567="Contents: Immunodeficiency states non HIV";
var content_f15_12_15567=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Immunodeficiency states non HIV",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Immunodeficiency states non HIV",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antibody deficiencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21321\">",
"           Agammaglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/28/17866\">",
"           Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/45/38617\">",
"           Common variable immunodeficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/32/21001\">",
"           Hyperimmunoglobulin M syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/60/13258\">",
"           IgG subclass deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35078\">",
"           IgG subclasses: Physical properties, genetics, and biologic functions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/32/38409\">",
"           Intravenous immune globulin: Adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/29/9688\">",
"           Pathogenesis of common variable immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/48/24326\">",
"           Primary humoral immune deficiencies: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/63/24570\">",
"           Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30998\">",
"           Selective IgA deficiency: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/44/38597\">",
"           Selective IgE deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42168\">",
"           Selective IgM deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/51/17209\">",
"           Selective antibody deficiency with normal immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30457\">",
"           Treatment and prognosis of common variable immunodeficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chromosomal breakage syndromes associated with immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23497\">",
"           Ataxia-telangiectasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35493\">",
"           Bloom syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/27/439\">",
"           Nijmegen breakage syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Combined immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/27/2488\">",
"           Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/43/27320\">",
"           Adenosine deaminase deficiency: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28329\">",
"           CD3/T cell receptor complex disorders causing immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/58/40873\">",
"           Combined immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25637\">",
"           Purine nucleoside phosphorylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15176\">",
"           Severe combined immunodeficiency (SCID) with JAK3 deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/30/42471\">",
"           Severe combined immunodeficiency (SCID): An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/10\">",
"           Severe combined immunodeficiency (SCID): Specific defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20362\">",
"           T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/25001\">",
"           T cell receptor signaling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1316\">",
"           X-linked severe combined immunodeficiency (SCID)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42022\">",
"           ZAP-70 deficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunodeficiency disorders - General considerations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/26/43433\">",
"           Approach to the adult with recurrent infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30458\">",
"           Approach to the child with recurrent infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/48/24328\">",
"           Assessing the immunologic response to vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23656\">",
"           Flow cytometry for the diagnosis of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27401\">",
"           Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15178\">",
"           Immune function in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14087\">",
"           Immune globulin therapy in primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/58/43945\">",
"           Laboratory evaluation of the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8633\">",
"           Medical management of immune deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/9/31896\">",
"           Subcutaneous and intramuscular immune globulin therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/5/37978\">",
"           Pulmonary complications of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40295\">",
"           Syndromic immunodeficiencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other well defined immunodeficiency syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/36/30279\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/58/30629\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/246\">",
"           Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7992\">",
"           Cartilage-hair hypoplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22553\">",
"           Chronic mucocutaneous candidiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/12/22729\">",
"           DiGeorge syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/37/32343\">",
"           DiGeorge syndrome: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15608\">",
"           DiGeorge syndrome: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32153\">",
"           Hyperimmunoglobulin E syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25850\">",
"           IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30009\">",
"           Idiopathic CD4+ lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/426\">",
"           Idiopathic systemic capillary leak syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/8/12420\">",
"           Mannose-binding lectin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/14/19690\">",
"           Mannose-binding lectin deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4297\">",
"           Mendelian susceptibility to mycobacterial diseases (MSMD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30889\">",
"           NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4724\">",
"           NK cell deficiency syndromes: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36313\">",
"           Wiskott-Aldrich syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33384\">",
"           X-linked lymphoproliferative disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Phagocyte disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29542\">",
"           Acquired disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42278\">",
"           Chediak-Higashi syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10826\">",
"           Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11465\">",
"           Chronic granulomatous disease: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42966\">",
"           Cyclic neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42520\">",
"           Immune neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42920\">",
"           Inherited disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22953\">",
"           Leukocyte adhesion deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14280\">",
"           Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/37/10838\">",
"           Neutrophil-specific granule deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10647\">",
"           Overview and clinical assessment of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43620\">",
"           Primary disorders of phagocytic function: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Secondary immunodeficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7561\">",
"           Secondary immune deficiency due to miscellaneous causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/0/29706\">",
"           Secondary immune deficiency induced by drugs and biologics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38842\">",
"           Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-27CFED5BB2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_12_15567=[""].join("\n");
var outline_f15_12_15567=null;
